



Vaccines and Global Health: The Week in Review
22 January 2022 :: Issue 640
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. **This blog allows full text searching of over 23,000 entries.***

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director

Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

::

[Milestones - Perspectives](#)

:: *[Coronavirus \[COVID-19\] - WHO](#)*

:: *[Emergencies](#)*

:: *[Organization Announcements](#)*

:: *[Journal Watch](#)*

Milestones - Perspectives

.....
.....

WHO - 150th session of the Executive Board

24 – 29 January 2022

Virtual event: <https://www.who.int/about/governance/executive-board/executive-board-150th-session>

EB150 Main Documents *[Selected]*

EB150/1

Provisional agenda

EB150/1 (annotated)

Provisional agenda (annotated)

EB150/7

Political declaration of the third high-level meeting of the General Assembly on the prevention and control of noncommunicable diseases

EB150/7 Add.1

Political declaration of the third high-level meeting of the General Assembly on the prevention and control of noncommunicable diseases

EB150/8

The global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections

EB150/9

Global strategy for tuberculosis research and innovation

EB150/10

Road map for neglected tropical diseases 2021–2030

EB150/11

Immunization Agenda 2030

EB150/12

Infection prevention and control

EB150/13

Global road map on defeating meningitis by 2030

EB150/15

Strengthening WHO preparedness for and response to health emergencies

EB150/17

Standing Committee on Pandemic and Emergency Preparedness and Response

[EB150/18](#)

Public health emergencies: preparedness and response
WHO's work in health emergencies

[EB150/19](#)

Influenza preparedness

[EB150/20](#)

Global Health for Peace Initiative

[EB150/21](#)

Poliomyelitis
Poliomyelitis eradication

[EB150/22](#)

Poliomyelitis
Polio transition planning and polio post-certification

[EB150/23](#)

Maternal, infant and young child nutrition
Comprehensive implementation plan on maternal, infant and young child nutrition: biennial report

.....
.....

CEPI

Bill & Melinda Gates Foundation and Wellcome pledge \$300 million to CEPI to fight COVID-19 and combat threat of future pandemics

This news announcement forms part of CEPI's [100 Days Mission](#), a campaign delving into how we can compress the vaccine development timeline to 100 days, while also counting down to CEPI's Global Pandemic Preparedness Summit taking place in March, 2022.

OSLO, Norway; January 19, 2022 –The Coalition for Epidemic Preparedness Innovations (CEPI) this week celebrates its fifth birthday with US\$300 million in pledges from the Bill & Melinda Gates Foundation and Wellcome to help fund its work on ending the acute phase of the COVID-19 pandemic and its global plan to take the threat of future pandemics off the table. The two philanthropic foundations were co-founders of CEPI at Davos in 2017, alongside the Governments of Norway and India, and the World Economic Forum.

The financial pledges—which together contribute towards the coalition's [\\$3.5 billion](#) fundraising target—will help advance CEPI's efforts to further COVID-19 vaccine R&D through investments in the development of the 'next generation' of COVID-19 vaccines, designed to protect against newly emerging variants and for use in low-resource settings.

The funding commitments will also provide critical support to ambitious initiatives set out by CEPI in its [six-point pandemic preparedness plan](#) to build a future world that is better prepared for emerging infectious disease outbreaks.

CEPI aims to reduce global epidemic and pandemic risk by preparing for known disease threats through the development of vaccines against its priority pathogens (Chikungunya, Lassa fever, MERS, Nipah, Rift Valley fever) and making them globally accessible. Focussing on Disease X, CEPI's plan also aims to build on innovations seen in the current pandemic and transform the response to the next novel coronavirus by developing all-in-one coronavirus vaccines designed to protect against multiple SARS-CoV-2 variants and other Betacoronaviruses*. Such tools could take the world beyond the current 'one bug, one drug' method and provide broad protection against current and future coronavirus threats.

Dr. Richard Hatchett, Chief Executive Officer, CEPI, said, "The crucial funds that have been pledged set CEPI on a positive trajectory towards our ultimate US\$3.5 billion funding goal. Achieving this funding target will enable CEPI to further advance, and enable equitable access to, life-saving vaccines and help the world develop ground-breaking new technologies including universal vaccines against Betacoronaviruses.

"Both these Foundations have shown incredible leadership with regards to global health, and we are enormously grateful to them for their visionary contribution to our work. If fully funded, CEPI's ambitious plan will revolutionise the way the world deals with future epidemics and could prevent us ever again having to suffer the devastation of a pandemic like COVID-19.

"The future we envisage can only be realised if the world steps up now to make the investments needed to build on the scientific advances made in response to the COVID-19 pandemic. CEPI calls on political, industry, academic, philanthropic, and civil society leaders to join us and support our bold plan."...

.....

[CEPI and Institut Pasteur de Dakar partner to advance COVID-19 vaccine manufacturing in Africa](#)

DAKAR, Senegal and OSLO, Norway; 18 January 2022: The Coalition for Epidemic Preparedness Innovations (CEPI) and the Institut Pasteur de Dakar (IPD) have signed a Memorandum of Understanding (MoU) to formalize the partnership between the two organizations to advance IPD's MADIBA project, a regional manufacturing hub for COVID-19 and other vaccines in Dakar, Sénégal. In its initial phase, IPD's new modular facility will manufacture up to 300 million doses of COVID-19 vaccine annually for use in Africa.

With the manufacturing facility in advanced construction, IPD is on track to start vaccine production in the third quarter of 2022. IPD has previously signed an MOU with BioNTech to pursue mRNA vaccine manufacturing and is actively exploring partnerships with other vaccine companies to produce licensed COVID-19 vaccines in its new manufacturing facility. In the future, IPD plans to expand to produce vaccines against other pathogens that are relevant to the region – potentially also new vaccines funded by CEPI.

CEPI will provide strategic and technical support to IPD's MADIBA project to advance the development and delivery of vaccines manufacturing in Africa. CEPI will also advise on the implementation of an innovative vaccine filling and delivery solution, licensed from MedInstill/INTACT Solutions and developed with CEPI's funding and support...

.....
.....

IHR Emergency Committee - COVID-19

Statement on the tenth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic

19 January 2022

Statement

[Excerpts]

...The Committee unanimously agreed that the COVID-19 pandemic still constitutes an extraordinary event that continues to adversely affect the health of populations around the world, poses a risk of international spread and interference with international traffic, and requires a coordinated international response. As such, **the Committee concurred that the COVID-19 pandemic remains a PHEIC and offered its advice to the Director-General.**

The Director-General determined that the COVID-19 pandemic continues to constitute a PHEIC. He accepted the advice of the Committee and issued the Committee's advice to States Parties as Temporary Recommendations under the IHR

The Emergency Committee will be reconvened within three months or earlier, at the discretion of the Director-General. The Director-General thanked the Committee for its work....

Temporary Recommendations to States Parties

The Committee identified the following actions as critical for all countries:

[1] MODIFIED: Continue to use evidence-informed public health and social measures, therapeutics, diagnostics, and vaccines for COVID-19, and to share response experiences with WHO. States Parties are advised to regularly adjust their response strategies by monitoring their epidemiological situation, assessing their vulnerabilities including their health system capacity, as well as considering the adherence to and attributable impact of individual and combined PHSM. Where isolation and quarantine of large numbers of cases and contacts is potentially disrupting critical infrastructure (including health care services), States Parties may need to modify isolation and quarantine periods, with the introduction of testing, to balance the risks with the continuation of key functions, using a risk-based approach. [Technical Brief on enhancing Readiness for Omicron](#) and [Considerations for implementing and adjusting public health and social measures in the context of COVID-19](#).

[2] MODIFIED: Take a risk-based approach to mass gathering events by evaluating, mitigating, and communicating risks. Recognizing that there are different drivers and risk tolerance for mass gatherings and mass migrations, and the particular challenges for fragile and vulnerable States Parties, it is critical to consider the epidemiological context (including the prevalence of variants of concern and the intensity of transmission), surveillance, contact tracing and testing capacity, as well as adherence to PHSM when conducting this risk assessment in line with WHO guidance. [Key planning recommendations for mass gatherings in the context of COVID-19](#).

[3] MODIFIED: Achieve the WHO call to action to have at least 70% of all countries' populations vaccinated by the start of July 2022 and integrate COVID-19 vaccination into routine health services. In accordance with advice from SAGE and WHO interim statements, States Parties are requested to share vaccine doses to increase global equity and to use a stepwise approach to vaccination, prioritizing those at highest risk from COVID-19, considering an evidence-informed use of booster vaccination, and taking into account evolving data on population level immunity. To enhance vaccine uptake, States Parties are encouraged to assess enablers and barriers to vaccination. Vaccination programmes should continue to prioritize vulnerable populations, including health workers, older people, people with underlying conditions, immunocompromised individuals with insufficient access to treatment, migrants, refugees, people living in fragile settings, sea farers, and air crews. [Interim Statement on COVID-19 vaccines in the context of the circulation of the Omicron SARS-CoV-2 Variant from the WHO Technical Advisory Group on COVID-19 Vaccine Composition \(TAG-CO-VAC\); Link to WHO SAGE Prioritization Roadmap](#)

[4] MODIFIED: Enhance surveillance of SARS-CoV-2 and continue to report to WHO to enable rapid identification, tracking, and evaluation of variants and continued monitoring of the pandemic's evolution and its control. States Parties should strengthen systems to collect and publicly share indicators to monitor the burden of COVID-19, such as hospitalization rates, severe disease, and excess mortality. States Parties are particularly encouraged to increase efforts to increase detection of infections in individuals where variants of interest and variants of concern may emerge. States Parties should strengthen mechanisms to link individual-level clinical, vaccination and genomic data to facilitate assessment of the impact of and vaccine effectiveness against VOC. States Parties should leverage and enhance existing systems such as the Global Influenza Surveillance and Response System (GISRS), as well as other national, regional, and global networks to integrate respiratory disease surveillance and prioritize monitoring circulation of SARS-CoV-2, relative proportions of SARS-CoV-2 variants, and circulation of other co-circulating respiratory viruses, including influenza. [Guidance for surveillance of SARS-CoV-2 variants; SARS-CoV-2 genomic sequencing for public health goals](#)

[5] MODIFIED: States Parties should ensure that there is sufficient surge capacity for critical SARS-CoV-2 clinical care and post COVID-19 condition, and for the maintenance of essential health services, and should plan for the restoration of health services at all levels with sufficient funding, supplies, and human resources. Specific to the risk of evolving new lineages, special attention may be needed for ensuring access to treatment for treatable immunosuppressive disease. States Parties should enhance access to health for all by strengthening health and social systems to cope with the impacts of the pandemic, especially on children. [Building health systems resilience for universal health coverage and health security during the COVID-19 pandemic and beyond: WHO position paper](#)

[6] MODIFIED: Lift or ease international traffic bans as they do not provide added value and continue to contribute to the economic and social stress experienced by States Parties. The failure of travel restrictions introduced after the detection and reporting of Omicron variant to limit international spread of Omicron demonstrates the ineffectiveness of such measures over time. Travel measures (e.g. masking, testing, isolation/quarantine, and vaccination) should be based on risk assessments and avoid placing the financial burden on international travellers in accordance with Article 40 of the IHR. [WHO advice for international traffic in relation to the SARS-CoV-2 Omicron variant](#)

[7] EXTENDED: Do NOT require proof of vaccination against COVID-19 for international travel as the only pathway or condition permitting international travel given limited global access and inequitable distribution of COVID-19 vaccines. State Parties should consider a risk-based approach to the facilitation of international travel by lifting or modifying measures, such as testing and/or quarantine requirements, when appropriate, in accordance with the WHO guidance. [Interim position paper: considerations regarding proof of COVID-19 vaccination for international travellers](#); [Policy considerations for implementing a risk-based approach to international travel in the context of COVID-19](#)

[8] MODIFIED: Recognize all vaccines that have received WHO Emergency Use Listing and all heterologous vaccine combinations as per SAGE recommendations, including in the context of international travel. States Parties are also requested to support research to derive the optimal vaccination strategy for reducing infection, morbidity and mortality. [Interim Recommendations for heterologous COVID-19 Vaccine Schedules](#) ; [WHO Emergency Use Listing](#)

[9] MODIFIED: Address community engagement and communications gaps and challenges posed by infodemics at national and local levels to reduce COVID-19 transmission, counter misinformation and threats to frontline workers, and improve COVID-19 vaccine acceptance, where applicable. This will require reinforcing messages that a comprehensive public health response is needed, including the continued use of PHSM alongside increasing vaccination coverage. Given the rapidly evolving situation and to promote trust and adherence, States Parties should explain clearly and transparently the rationale for the changes of policies and PHSM, with a view to balance risks and benefits of such changes. These communications need to be tailored to different population groups, including those considered as most vulnerable. [Link to WHO risk communications resources](#).

[10] MODIFIED: Support timely uptake and monitoring of WHO recommended therapeutics by addressing challenges with accessibility and appropriate use. Local production and technology transfer can contribute to global equitable access to therapeutics. States Parties are advised to establish COVID-19 therapeutics resistance monitoring systems, using appropriate testing strategies and strengthening their surveillance system. In addition, States Parties are requested to support pharmacovigilance cohort studies and reporting systems to detect adverse events following administration of new therapeutics. [Therapeutics and COVID-19: living guideline](#)

[11] NEW: Conduct epidemiological investigations of SARS-CoV-2 transmission at the human-animal interface and targeted surveillance on potential animal hosts and reservoirs. Real time monitoring and data sharing on SARS-Cov-2 infection, transmission and evolution in animals will assist global understanding of the virus epidemiology and ecology, the potential for evolution of new variants in animal populations, their timely identification, and assessment of their public health risks. [Statement from the Advisory Group on SARS-CoV-2 Evolution in Animals](#)

.....
.....

COVAX

[COVAX delivers its 1 billionth COVID-19 vaccine dose](#)

16 January 2022

On 15 January 2022, a shipment of 1.1 million COVID-19 vaccines to Rwanda included the billionth dose supplied via COVAX.

Together with our partners, COVAX is leading the largest vaccine procurement and supply operation in history, with deliveries to 144 countries to date.

But the work that has gone into this milestone is only a reminder of the work that remains. As of 13 January 2022, out of 194 Member States, 36 WHO Member States have vaccinated less than 10% of their population, and 88 less than 40%.

COVAX's ambition was compromised by hoarding/stockpiling in rich countries, catastrophic outbreaks leading to borders and supply being locked. And a lack of sharing of licenses, technology and know how by pharmaceutical companies meant manufacturing capacity went unused.

COVAX is working with governments, manufacturers and partners to ensure that when countries receive vaccines they can get them to people quickly.

With updated vaccines in the pipeline, now is the moment for all citizens to demand that governments & pharmaceutical companies share health tools globally & bring an end to the death & destruction cycles of this pandemic, limit new variants and drive a global economic recovery.

.....
.....

ICMRA COVID-19 Omicron variant workshop

12 January 2022 [published 20 Jan 2022]

Co-chairs: Peter Marks (FDA, US) and Marco Cavaleri (EMA, EU)

Welcome by Emer Cooke, ICMRA chair (EMA)

The 'COVID-19 Omicron variant' workshop is the third ICMRA vaccines workshop, following the workshop organised in June 2021 entitled 'Vaccine development: future steps'. **The objective of this workshop was to reach international regulatory alignment on dealing with Omicron variant, on the criteria for the selection of adapted vaccines and fostering a strategic discussion between all public health authorities on the long term needs against SARS-CoV-2...**

Closing remarks and next steps

While current vaccines are losing protection against Omicron with respect to infection and mild disease, there is still considerable protection from hospitalisation and severe COVID-19, especially after a booster dose. It is becoming increasingly clear that a booster dose is needed to extend vaccine protection.

Particularly from the perspective of a global strategy, additional boosters of current vaccines administered with short intervals to restore protection over time would not be the preferable approach to protect public health and a longer-term strategy should be defined.

With respect to updated vaccine composition, other alternatives should be considered besides a monovalent omicron vaccine as it is not yet defined what would be the preferable approach.

In principle, clinical data are needed for approving a new updated vaccine. Clinical studies should demonstrate that the immune response, measured as neutralising antibodies, with the updated vaccine

is superior to the immune response achieved with the prototype vaccine against the variant included in the updated vaccine. Cross-neutralisation of other variants of concern would be additional relevant evidence with respect to the breadth of coverage provided by the updated vaccine. These criteria have to be considered as a minimum requirement to support variant vaccine approval.

Global coordination of changes in vaccine composition to cover potential variants of concern will be important.

.....

Coronavirus [COVID-19] - WHO

Public Health Emergency of International Concern (PHEIC)

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

Weekly Epidemiological and Operational updates

Last update: 21 Jan 2022


Confirmed cases :: 340 543 962

Confirmed deaths :: 5 570 163

Vaccine doses administered: 9 571 502 663

.....

Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 16 January 2022**



**See [Annex 2: Data, table, and figure notes](#)

Weekly epidemiological update on COVID-19 - 18 January 2022

Overview

Globally, the number of new COVID-19 cases increased in the past week (10-16 January 2022), while the number of new deaths remained similar to that of the previous week.

Across the six WHO regions, over 18 million new cases were reported this week, a 20% increase, as

compared to the previous week. Over 45 000 new deaths were also reported. As of 16 January, over 323 million confirmed cases and over 5.5 million deaths have been reported worldwide.

Despite a slowdown of the increase in case incidence at the global level, all regions reported an increase in the incidence of weekly cases with the exception of the African Region, which reported a 27% decrease. The South-East Asia region reported the largest increase in new cases last week (145%), followed by the Eastern Mediterranean Region (68%). New weekly deaths increased in the South-East Asia Region (12%) and Region of the Americas (7%) while remaining approximately the same as the previous week in the other regions.

.....
.....

WHO Director General Speeches [selected]

<https://www.who.int/director-general/speeches>

Selected

18 January 2022

Speech

WHO Director-General's opening remarks at the media briefing on COVID-19 — 18 January 2022

:: The volcanic eruption near Tonga and subsequent tsunami requires an urgent response. With telecommunications down, WHO is on the ground in Tonga helping coordinate the response by channelling information between UN agencies, humanitarian partners and the Tongan government.

:: Omicron continues to sweep the world. Last week, there were more than 18 million reported cases. Make no mistake, Omicron is causing hospitalizations and deaths, and even the less severe cases are inundating health facilities.

:: Next week, the WHO Executive Board, which is made up of 34 Member States, will meet to discuss the world's health challenges. WHO will be working to accelerate progress on negotiations around a pandemic accord, as well as sustainable financing.

.....
.....

WHO SAGE Roadmap for prioritizing uses of COVID-19 vaccines

21 January 2022

An approach to optimize the global impact of COVID-19 vaccines, based on public health goals, global and national equity, and vaccine access and coverage scenarios

Overview

Given the urgency and wide-ranging effects of the COVID-19 pandemic, SAGE has developed an approach to help inform deliberation around the range of recommendations that may be appropriate under different epidemiologic and vaccine supply conditions. To assist in developing recommendations for use of vaccines against COVID-19, SAGE proposes a Roadmap for Prioritizing Uses of COVID-19 Vaccines that considers priority populations for vaccination based on epidemiologic setting and vaccine supply scenarios. This Roadmap builds on the WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination.

PDF: <https://apps.who.int/iris/rest/bitstreams/1406385/retrieve>

Preamble

This interim guidance constitutes a major revision of the WHO SAGE roadmap for prioritizing uses of COVID-19 vaccines, first issued October 2020, and updated in November 2020 and July 2021. It is based on work conducted by the SAGE Working Group on COVID-19 Vaccines and SAGE members, from October 2021 to January 2022, including consultation with RITAG1 chairs, and dedicated discussions at extraordinary meetings of the Strategic Advisory Group of Experts (SAGE) on Immunization on 7 December 2021 and 19 January 2022 (1).

This revised Roadmap takes into account increasing vaccine availability, vaccine coverage rates, and the evolving epidemiological situation including COVID-19 variants of concern. Scenarios in which vaccination coverage exceeds 50% of the population are considered, as are topics such as vaccine use in children and adolescents and prioritization of additional and booster doses in relation to vaccination coverage rates. To assist countries in developing recommendations for optimized use of vaccines against COVID-19, priority-use groups for vaccination (both primary series and booster doses) are identified based on epidemiological scenarios, public health goals, and vaccine coverage scenarios (in accordance with WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination (2)).

This Roadmap is complementary to the Strategy to achieve global Covid-19 vaccination by mid-2022 (3) issued in September 2021, which was developed by WHO in collaboration with its COVAX partners and key regional and national stakeholders, and which specifies national vaccine coverage categories. The Roadmap emphasizes the importance of prioritizing the distribution of increasingly available vaccine supply to optimize impact on health, socioeconomic conditions, and equity, and focuses on in-country vaccine policies....

Selected Chart

Table 1: Prioritized use of primary series and booster doses by vaccine coverage rates in higher priority-use (I & II) groups

Priority-use groups†	Vaccine coverage rates of <i>higher priority-use</i> (I & II) groups			
	Low → Moderate → High → Very high			
I. Highest priority-use Older adults Health workers Immunocompromised persons	Primary series + Additional dose* / Booster**			
II. High priority-use Adults with comorbidities Pregnant persons Teachers and other essential workers Disadvantaged sociodemographic subpopulations at higher risk of severe COVID-19		Primary series + Booster		
III. Medium priority-use Remaining adults Children and adolescents with comorbidities			Primary series + Booster	
IV. Lowest priority-use Healthy children and adolescents				Primary series + Booster (booster doses in children below the age of 12 years have not yet been assessed)

†Priority-use groups: The extent of risk of severe disease and death is the main determinant for assignment of a subgroup (or subpopulation) to a priority-use group. This criterion aligns with a specification of the human well-being principle in the WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccines. In addition, other specifications of that principle, including reducing societal and economic disruption and protecting essential health services, as well as of the national equity and reciprocity principles, are also used to justify assignment of some of the subgroups to a priority-use group.

**Additional dose:* Persons with moderate to severe immunocompromising conditions should receive an expanded primary vaccination series through an additional dose about 1–3 months after completion of the primary series (see Interim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons (4)). Such persons are also a high priority-use group for a subsequent (booster) dose.

***Booster dose:* The optimal interval between completion of a primary series and administration of a booster dose has yet to be determined, and depends on epidemiological setting, vaccine product, targeted age groups, background seroprevalence, and circulation of specific variants of concern. As a general principle, dependent on vaccine product, an interval of 4–6 months since completion of the primary series could be considered for countries experiencing significant loss of vaccine effectiveness against severe disease in the context of an impending or ongoing major surge of cases, while a longer interval could be considered for those countries currently not experiencing, or at low risk of, an increasing incidence of cases.

.....
.....

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 23 December 2021

[Full scale view available at title link above]

[No change from 23 December 2021]

.....

COVID Vaccines/Therapeutics - Developer/Manufacturer Announcements

[Selected press releases/announcements from organizations from WHO EUL/PQ listing above and other organizations]

AstraZeneca

Press Releases - No new digest announcements identified

Bharat Biotech

Press Releases - No new digest announcements identified

BioCubaFarma – Cuba

Últimas Noticias

22 de Enero, 2022

Mambisa: Candidato vacunal anti-covid-19 para administración por vía nasal demuestra seguridad e inmunogenicidad y avanza en ensayos clínicos

[Mambisa: Anti-covid-19 vaccine candidate for nasal administration demonstrates safety and immunogenicity and advances in clinical trials]

19 de Enero, 2022

[Avanza investigación con el candidato vacunal Mambisa](#)

BioCubaFarma

[Research advances with the vaccine candidate Mambisa]

19 de Enero, 2022

[Más de cuatro millones de cubanos han recibido dosis de refuerzo contra la COVID-19.](#)

BioCubaFarma

[More than four million Cubans have received booster doses against COVID-19.]

CanSinoBIO

News - *[Website not responding at inquiry]*

Clover Biopharmaceuticals - China

News

[Clover's Final SPECTRA Phase 2/3 Clinical Trial Efficacy Data Is Published in The Lancet](#)

[COVID-19 vaccine candidate, SCB-2019]

January 20, 2022

Curevac [Bayer Ag – Germany]

News

January 17, 2022

[CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry](#)

Gamaleya National Center

Latest News and Events - *No new digest announcements identified [See Russia/RFID below]*

IMBCAMS, China

Home - *No new digest announcements identified*

Janssen/JNJ

Press Releases - *No new digest announcements identified*

Moderna

Press Releases - *No new digest announcements identified*

Novavax

Press Releases

[Australia Therapeutic Goods Administration \(TGA\) Grants Provisional Registration for Novavax COVID-19 Vaccine](#)

Jan 19, 2022

Pfizer

Recent Press Releases

01.18.2022

Pfizer Shares In Vitro Efficacy of Novel COVID-19 Oral Treatment Against Omicron Variant

NEW YORK, January 18, 2022 -- Pfizer Inc. (NYSE: PFE) today shared results from multiple studies demonstrating that the in vitro efficacy of nirmatrelvir, the active main protease (Mpro) inhibitor of PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), is maintained against the SARS-CoV-2 variant Omicron. Taken together, these in vitro studies suggest that PAXLOVID has the potential to maintain plasma concentrations many-fold times higher than the amount required to prevent Omicron from replicating in cells...

Sanofi Pasteur

Press Releases - No new digest announcements identified

Serum Institute of India

NEWS & ANNOUNCEMENTS - No new digest announcements identified

Sinopharm/WIBPBIBP

News - No new digest announcements identified

Sinovac

Press Releases

Collaboration in Africa, COVID-19 prevention and control working together with SINOVAC

2022/01/20 Event

Vector State Research Centre of Virology and Biotechnology

Home - No new digest announcements identified

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]

.....

GSK

Press releases for media

19 January 2022 **Tony Wood appointed Chief Scientific Officer designate, GSK**

:: Tony Wood to assume full accountability for GSK R&D in August 2022

:: Hal Barron to transition in August 2022 from CSO to a GSK Non-Executive Director with additional responsibilities to support R&D

Merck

News releases

January 18, 2022

Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine

Novartis

News - No new digest announcements identified

SK Biosciences

Press releases

[SK bioscience Complete Recruitment for Phase III Clinical Trial of COVID-19 Vaccine](#)

Recruitment of global Phase III clinical trial of 'GBP510' completed, with vaccine expected to be au...
2022. 01. 18

Valneva

Press Releases

January 19, 2022

[Valneva's Inactivated COVID-19 Vaccine Candidate Shown to Neutralize Omicron Variant](#)

:: Preliminary laboratory studies demonstrate that three doses of Valneva's inactivated COVID-19 vaccine candidate VLA2001 induced neutralization of the Omicron variant (B.1.1.529 lineage)

:: 100% of tested serum samples presented neutralizing antibodies against the ancestral virus and Delta variant, and 87% against the Omicron variant

.....
.....

[UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 22 Jan 2022](#)

An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 10/22/2021 reported]



33

vaccines approved for use by at least one national regulatory authority ¹



10

vaccines in WHO's Emergency Use Listing



17.7bn

doses secured globally



\$2 - \$40

reported vaccine price range per dose



2.8bn

doses COVAX has secured from funded agreements and confirmed donations



1.0bn


doses shipped through COVAX to 144 countries



COVID-19 Global Targets and Progress Tracker - IMF

The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges. The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.

Progress Towards 70% Vaccine Coverage by Mid-2022 1/



Source: IMF and WHO Staff calculations.

1/ Broadly, all countries that are at risk of missing the 70% target by mid-2022 are also below 40% as of early Jan 2022.




Global COVID-19 Access Tracker

<https://www.covid19globaltracker.org/>

Global COVID-19 Access Tracker

The ACT-Accelerator and Multilateral Leaders Task Force Global COVID-19 Access Tracker (GCAT) is a dynamic tool to transparently track progress towards the global targets for access to COVID-19 vaccines, treatments, tests and PPE.

Last Updated on 21 Jan, 2022.




Global Dashboard on COVID-19 Vaccine Equity

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 22 Jan 2022]: <https://data.undp.org/vaccine-equity/>

See also visualization on [Vaccine Access](#) and [Vaccine Affordability](#)



Duke – Launch and Scale Speedometer

The Race for Global COVID-19 Vaccine Equity

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables

and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution [accessed 24 July 2021]

[See our COVID Vaccine Purchases research](#)



[See our COVID Vaccine Manufacturing research](#)

[See our COVID Vaccine Donations & Exports research](#)

Overview of donations by top 10 donating countries

Bar chart is ordered by total number of doses pledged.
Donut charts are ordered by proportion of pledged donations shipped.

Country Category:
Top 10 Donating Countries



Data updated on Jan 21st 2022

Duke | GLOBAL HEALTH
Innovation Center

.....
.....

COVID Vaccines – OCHA:: HDX

[COVID-19 Data Explorer: Global Humanitarian Operations](#)

COVID-19 Vaccine Roll-out

22 Jan 2022 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | [DATA](#)

Global COVID-19 Figures: 340M total confirmed cases; 5.6M total confirmed deaths

Global vaccines administered: 9.79B

Number of Countries: 30
COVAX Allocations Round 4-9 (Number of Doses): 220M
COVAX Delivered (Number of Doses): 280M
Other Delivered (Number of Doses): 340M
Total Delivered (Number of Doses): 620M
Total Administered (Number of Doses): 470M

.....
.....


Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]

<https://data.covid19taskforce.com/data>

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed **22 Jan 2022**: <https://data.covid19taskforce.com/data> The global view below is complemented by country-specific dashboards [here](#).



.....
.....

Our World in Data

[Coronavirus \(COVID-19\) Vaccinations](#) [Accessed 22 Jan 2022]

:: [60.4%](#) of the world population has received at least one dose of a COVID-19 vaccine.


:: [9.85 billion doses](#) have been administered globally, and [29.23 million](#) are now administered each day.

:: Only [9.5%](#) of people in low-income countries have received at least one dose.

Share of the population fully vaccinated against COVID-19, Jan 21, 2022

Our World in Data

Total number of people who received all doses prescribed by the initial vaccination protocol, divided by the total population of the country.



Source: Official data collated by Our World in Data - Last updated 22 January 2022, 19:30 (London time)

Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

OurWorldInData.org/coronavirus • CC BY


Dec 13, 2020 Jan 21, 2022

Share of the population fully vaccinated against COVID-19, Jan 21, 2022

Our World in Data

Total number of people who received all doses prescribed by the initial vaccination protocol, divided by the total population of the country.

+ Add country



Source: Official data collated by Our World in Data - Last updated 22 January 2022, 19:30 (London time)

Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

OurWorldInData.org/coronavirus • CC BY

Dec 13, 2020 Jan 21, 2022

.....
.....

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

HHS

News

No new digest content identified.

FDA

Press Announcements

[January 21, 2022 - FDA Takes Actions to Expand Use of Treatment for Outpatients with Mild-to-Moderate COVID-19](#)

Today, the U.S. Food and Drug Administration took two actions to expand the use of the antiviral drug Veklury (remdesivir) to certain non-hospitalized adults and pediatric patients for the treatment of mild-to-moderate COVID-19 disease. This provides another treatment option to reduce the risk of hospitalization in high-risk patients. Previously, the use of Veklury was limited to patients requiring hospitalization.//

Vaccines and Related Biological Products Advisory Committee- FDA

<https://www.fda.gov/advisory-committees/blood-vaccines-and-other-biologics/vaccines-and-related-biological-products-advisory-committee>

No meetings on [calendar](#)

.....

White House [U.S.]

Briefing Room – Selected Major COVID Announcements

[Press Briefing by White House COVID-19 Response Team and Public Health Officials](#)

January 21, 2022 Press Briefings

U.S. Department of State

<https://www.state.gov/coronavirus/releases/>

Media Notes

No new digest content identified.

.....
.....

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency

News & Press Releases

[News: International regulators' recommendations on COVID-19 vaccines and the Omicron variant \(new\)](#)

Last updated: 21/01/2022

[See Perspectives above for detail]

News: International regulators' recommendations on COVID-19 vaccines and the Omicron variant (new)

Last updated: 21/01/2022

.....

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

Latest Updates

Publication

Communicable disease threats report, 16-22 January 2022, week 3

Publication - 21 Jan 2022

News

Weekly epidemiological update: Omicron variant of concern (VOC) – week 2 (data as of 20 January 2022) EU/EEA


Epidemiological update - 21 Jan 2022

Publication

Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 50 years and older, ECDC multi-country study – first update

Technical report - 20 Jan 2022

.....



Accessed 22 Jan 2022

<https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab>

.....

European Commission

<https://ec.europa.eu/commission/presscorner/home/en>

Press release 19 January 2022

New Pact on Migration and Asylum: new mandate, new start for the European Union Agency for Asylum

Today, the new European Union Agency for Asylum starts work with its reinforced mandate, building on the achievements of its predecessor, the European Asylum Support Office

Press release 19 January 2022

EU Cohesion policy: Almost €385.5 million from the EU Solidarity Fund to 19 countries to tackle the coronavirus health emergency

The Commission completed the payments of the EU Solidarity Fund (EUSF) assistance to tackle the coronavirus health emergency to 19 countries for a total amount of almost €385.5 million.

Press release 18 January 2022

Afghanistan: EU supports the education, health and livelihoods of the Afghan people with €268.3 million

In the major humanitarian crisis Afghanistan is facing, the EU has launched projects worth €268.3 million, stepping up vital support to the Afghan population.


Press release 17 January 2022

EU at forefront of global humanitarian response: €1.5 billion for 2022

Humanitarian crises around the world continue to rise. While conflicts and violence are the source of major humanitarian needs, the situation is increasingly being worsened by natural disasters, such as drought or floods, fuelled by climate change and environmental degradation.

.....
.....

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment





Accessed 22 Jan 2022. Full scale, interactive dashboard available at:
<https://africacdc.org/covid-19-vaccination/>

.....

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"

<https://sputnikvaccine.com/newsroom/pressreleases/>

Press Releases

[Sputnik V demonstrates strong protection against Omicron variant, with over 2 times higher virus neutralizing activity compared to the Pfizer vaccine according to a unique independent comparative study conducted by the Spallanzani Institute in Italy](#)

Press release, 20.01.2022

.....

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare

<https://www.mohfw.gov.in/>

COVID-19 INDIA as on :
 22 January 2022, 08:00
 IST (GMT+5:30)

(↑↓ Status change since
 yesterday)

Active (5.43%)

2113365 (94540↑)

Discharged (93.31%)

36301482 (242676↑)

Deaths (1.26%)

488884 (488↑)

COVID-19 Vaccination
 as on : 22 January
 2022, 08:00 IST
 (GMT+5:30)

Total Vaccination : 1,61,16,60,078 (67,49,746↑)

[Revised Comprehensive Guidelines for Management of COVID-19 in Children and Adolescents \(below 18 years\)](#)

20.01.2022

Government of India – Press Information Bureau

Latest Press Releases

[COVID - 19 Vaccination Update - Day 372](#)

:: India's cumulative vaccination coverage crosses 161.81 crore

:: More than 61 lakh Vaccine doses administered today till 7 pm

Posted On: 22 JAN 2022 7:52PM by PIB Delhi

Indian Council for Medical Research (ICMR)

<https://www.icmr.gov.in/media.html>

Press Releases

No new digest content identified.

.....
.....

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Over 2.95b COVID-19 vaccine doses administered on Chinese mainland

2022-01-21

More than 2.95 billion COVID-19 vaccine doses had been administered on the Chinese mainland as of Wednesday, data from the National Health Commission showed Thursday.

Beijing confirms 5 cases, tightens virus measures

2022-01-21

Beijing is facing a severe and complicated COVID-19 epidemic control and prevention situation as an increasing number of cases have occurred in several districts this week, a senior official said on Thursday.

Beijing reported five new confirmed locally transmitted COVID-19 cases on Thursday, including three who had reported positive nucleic acid tests on Wednesday.

Following that test, a further test confirmed viral infections, bringing the total number of positive and confirmed cases in the latest outbreaks to 11.

All of the new patients work in the cold chain industry. The Delta variant of the novel coronavirus was detected in samples collected from those cases.

"The whole genome sequencing of one of the new cases is in accord with a previous case reported on Tuesday, which means they are in the same transmission chain," Pang Xinghuo, deputy director of the Beijing Center for Disease Control and Prevention, said at a news conference...

China adopts faster mass testing for COVID-19

2022-01-20

BEIJING — Chinese health authorities have adopted faster-pooled tests for the coronavirus that allow professional labs to process 20 samples at a time.

The updated testing techniques, based on the current practice of putting five or 10 swab samples together and testing as one, are aimed at sharply boosting the efficiency of virus testing, said the State Council inter-agency task force for COVID-19 response.

The new testing approach will be introduced across the country while ensuring quality results, it said...

.....
.....
.....

Emergencies

POLIO

Public Health Emergency of International Concern (PHEIC)

<https://polioeradication.org/polio-today/polio-now/this-week/>

Polio this week as of 19 January 2022

:: ...WHO Executive Board...The Secretariat has prepared two reports, which will inform Member State discussions, namely on polio eradication, and on polio transition planning and post-certification.

:: On polio eradication, the [report](#) provides an update on work towards Goals 1 and 2 of the Polio Eradication Strategy 2022–2026. On transition and post-certification, the [report](#) provides an update on the implementation of the Strategic Action Plan on Polio Transition (2018-2023) within the context of COVID-19.

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):

- **Cote d'Ivoire:** two cVDPV2 positive environmental samples
- **Nigeria:** three cVDPV2 cases and 11 cVDPV2 positive environmental samples

.....

Afghanistan conducts first polio vaccination campaign in 2022

Kabul, 17 January 2022 – The first national polio immunization campaign for 2022 begins this week, 17-20 January 2022, targeting 9.9 million children aged 0–59 months across the country.

The recent campaign in November 2021 delivered polio vaccinations to 8.5 million children under the age of 5 while the December campaign vaccinated more than 8 million children. In total, 2.6 million children have now been vaccinated for the first time in more than 3 years.

2021 was the year with the lowest ever polio transmission in Afghanistan, providing an unprecedented opportunity to interrupt transmission of wild poliovirus and achieve eradication. Four cases of wild poliovirus type 1 (WPV1) were reported: the first, in Ghazni province in January, and 3 in Kunduz province in October and November.

In response to the detection of 3 cases of WPV1 in Kunduz earlier this month, the polio programme also conducted a third case response campaign in 7 provinces in order to stop the outbreak and protect children from the crippling but preventable disease.

"As we begin 2022, we have our best opportunity yet to end polio in Afghanistan," said Dr Dapeng Luo, WHO Representative in Afghanistan. "To reach that goal, we have 5 more campaigns planned for 2022 and it is critical that we maintain this momentum to reach our final goal of zero cases." ...

.....

.....

Disease Outbreak News (DONs)

:: Hepatitis E virus - Chad 17 January 2022

.....

.....

WHO/OCHA Emergencies

Health emergencies list - WHO

"The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences."

Afghanistan crisis

:: First polio vaccination campaign for 2022 under way 17 January 2022

Crisis in Northern Ethiopia *[Last apparent update: 1 June 2021]*

Ebola outbreak, Democratic Republic of the Congo, 2021 *[Last apparent update: 17 Aug 2021]*

Ebola outbreak outbreak, N'Zerekore, Guinea, 2021 *[Last apparent update: 17 Aug 2021]*

Coronavirus disease (COVID-19) pandemic *[See COVID above]*

Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020

[Last apparent update: 17 Aug 2021]

Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020

[Last apparent update: 17 Aug 2021]

Ebola outbreak, Democratic Republic of the Congo, 2018 *[Last apparent update: 24 July 2018]*

Yemen crisis *[Last apparent update: 12 February 2021]*

Syria crisis *[Last apparent update: 18 June 2021]*

Somalia crisis *[Last apparent update: 24 March 2018]*

Nigeria crisis *[Last apparent update: 1 Oct 2021]*

Ebola outbreak, Democratic Republic of the Congo, 2017 *[Last apparent update: 17 Aug 2021]*

Zika virus disease outbreak, 2015-2016 *[Last apparent update: 24 Jan 2020]*

Ebola outbreak: West Africa, 2014-2016 *[Last apparent update: 17 Aug 2021]*

Iraq crisis *[Last apparent update: 9 Jan 2008]*

South Sudan crisis *[Last apparent update: 23 Sep 2020]*

Avian influenza A (H7N9) virus outbreak *[Last apparent update: 13 September 2021]*

Middle East respiratory syndrome (MERS-CoV) outbreak *[Last apparent update: 8 July 2019]*

[Influenza A \(H1N1\) virus, 2009-2010 pandemic](#) [Last apparent update: 10 Aug 2010]

.....

[UN OCHA – Current Emergencies](#)

Current Corporate Emergencies

Afghanistan

[Earthquake in Badghis Province, Afghanistan - Flash Update No. 2 \(As of 21 January 2022, 12:00 local time \(Kabul\)\)](#)

Northern Ethiopia

[Ethiopia - Northern Ethiopia Humanitarian Update Situation Report, 20 January 2022](#)

...More than 145,000 children received measles vaccination in Tigray so far, but the campaign faces challenges including lack of fuel, cash, and cold chain capacity...

.....

.....

WHO & Regional Offices [to 22 Jan 2022]

<https://www.who.int/>

Selected News, Statements

20 January 2022

News release

[WHO publishes new global data on the use of clean and polluting fuels for cooking by fuel type](#)

20 January 2022

Departmental news

[U.S. EPA and WHO partner to protect public health](#)

20 January 2022

Departmental news

[Planning and budgeting tool for TB and drug-resistant TB testing](#)

20 January 2022

Departmental news

[WHO summary of Baseline report for UN Decade of Healthy Ageing is now available in all official UN languages](#)

19 January 2022

Statement

[Statement on the tenth meeting of the International Health Regulations \(2005\) Emergency Committee regarding the coronavirus disease \(COVID-19\) pandemic](#)

19 January 2022

Departmental news

WHO announces the update of the guidelines on the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults

18 January 2022

Departmental news

First WHO report highlights efforts to improving health and well-being of adolescents worldwide

16 January 2022

News release

COVAX delivers its 1 billionth COVID-19 vaccine dose

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: Cases drop for first time as Africa's fourth COVID-19 wave ebbs 20 January 2022

Brazzaville – Weekly COVID-19 cases in Africa have dropped significantly and deaths dipped for the first time since the peak of the fourth pandemic wave propelled by the Omicron variant. The decline nudges the continent past its shortest upsurge yet that lasted 56 days.

Newly reported cases fell by 20% in the week to 16 January, while deaths dropped by 8%. The decrease in deaths is still small and further monitoring is needed, but if the trend continues the surge in deaths will also be the shortest reported so far during this pandemic...

WHO Region of the Americas PAHO

:: PAHO calls for countries to prioritize rapid tests for those with COVID-19 symptoms 19 Jan 2022

As infections surge, testing should be expanded to alleviate pressure on hospitals. Those without symptoms should quarantine and follow public health measures. Washington D.C. 19 January 2022 (PAHO) – With COVID-19 surging throughout the Americas and demand for diagnostics higher than ever, the Pan American Health Organization Director Carissa F...

WHO South-East Asia Region SEARO

No new digest content identified

WHO European Region EURO

:: Two years of COVID-19: What it takes to run an emergency response across 53 countries 21-01-2022

:: Noncommunicable diseases in 53 countries: WHO/Europe presents new visual data tool 20-01-2022

:: The Omicron variant: sorting fact from myth 19-01-2022

WHO Eastern Mediterranean Region EMRO

:: Volunteering for the fight against malaria in Yemen 17 January 2022

:: Afghanistan conducts first polio vaccination campaign in 2022 17 January 2022

WHO Western Pacific Region

:: 18 January 2022 News release WHO supports whole-of-UN response to volcanic eruption and tsunami in Tonga

.....

WHO Events

<https://www.who.int/news-room/events/2>

[Selected]

150th session of the Executive Board

24 – 29 January 2022

Virtual event

World NTD Day 2022: Achieving health equity to end the neglect of poverty-related diseases

26 January 2022 14:00 – 15:00 CET

WHO consultation on COVID vaccines research: Why do we need a pan-sarbecovirus vaccine?

28 January 2022 13:00 – 19:00 CET

Mobilizing the World to Defeat Neglected Tropical Diseases

28 January 2022 16:00 – 17:15 CET

.....

New WHO Publications

<https://www.who.int/publications/i>

Selected Titles

21 January 2022

Annexes to the recommendations for use of the Pfizer–BioNTech vaccine BNT162b2 against COVID-19

21 January 2022

WHO SAGE Roadmap for prioritizing uses of COVID-19 vaccines

[See COVID above for detail]

21 January 2022

Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use...

20 January 2022

Review of Minamata convention initial assessment reports: key findings for health

.....

.....

.....

CDC/ACIP [U.S.] [to 22 Jan 2022]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

Latest News Releases, Announcements [Selected]

[CDC Statement on MMWR: COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021](#)

Thursday, January 20, 2022

[CDC Releases Updated Maps of America's High Levels of Inactivity](#)

Thursday, January 20, 2022

.....

[ACIP Meetings](#)

Next meeting scheduled for February 23-24, 2022

.....

[MMWR News Synopsis Friday, January 21, 2022](#)

Selected Content

:: [Surveillance Summaries: Disease Surveillance Among U.S.-Bound Immigrants and Refugees — Electronic Disease Notification System, United States, 2014–2019](#)

:: [Zika-Associated Birth Defects Reported in Pregnancies with Laboratory Evidence of Confirmed or Possible Zika Virus Infection — U.S. Zika Pregnancy and Infant Registry, December 1, 2015–March 31, 2018](#)

:: [Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022](#)

:: [Progress Toward Poliomyelitis Eradication — Afghanistan, January 2020–November 2021](#)

:: [Use of the Janssen \(Johnson & Johnson\) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices — United States, December 2021](#)

:: [Previously Released: Racial and Ethnic Disparities in Receipt of Medications for Treatment of COVID-19 — United States, March 2020–August 2021](#)

.....

[Coronavirus Disease 2019 \(COVID-19\)- CDC](#)

Approximately 25 announcements/reports/data summaries.

- 21 Jan [COVID-19 Travel Recommendations by Country](#)
- 21 Jan [Cases in the U.S.](#)
- 21 Jan [EARLY RELEASE: Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022](#)
- 21 Jan [EARLY RELEASE: COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021](#)
- 21 Jan [Overall US COVID-19 Vaccine Distribution and Administration Update as of Fri, 21 Jan 2022 06:00:00 EST](#)

.....

.....

Africa CDC [to 22 Jan 2022]

<http://www.africacdc.org/>

News

No new digest content identified.

.....

.....

China CDC <http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 22 Jan 2022]

<http://en.nhc.gov.cn/>

News

Jan 22: Daily briefing on novel coronavirus cases in China

On Jan 21, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 63 new cases of confirmed infections.

Beijing confirms 5 cases, tightens virus measures

2022-01-21

Beijing is facing a severe and complicated COVID-19 epidemic control and prevention situation as an increasing number of cases have occurred in several districts this week, a senior official said on Thursday.

Beijing reported five new confirmed locally transmitted COVID-19 cases on Thursday, including three who had reported positive nucleic acid tests on Wednesday.

Following that test, a further test confirmed viral infections, bringing the total number of positive and confirmed cases in the latest outbreaks to 11.

All of the new patients work in the cold chain industry. The Delta variant of the novel coronavirus was detected in samples collected from those cases.

"The whole genome sequencing of one of the new cases is in accord with a previous case reported on Tuesday, which means they are in the same transmission chain," Pang Xinghuo, deputy director of the Beijing Center for Disease Control and Prevention, said at a news conference...

China adopts faster mass testing for COVID-19

2022-01-20

BEIJING — Chinese health authorities have adopted faster-pooled tests for the coronavirus that allow professional labs to process 20 samples at a time.

The updated testing techniques, based on the current practice of putting five or 10 swab samples together and testing as one, are aimed at sharply boosting the efficiency of virus testing, said the State Council inter-agency task force for COVID-19 response.

The new testing approach will be introduced across the country while ensuring quality results, it said...

National Medical Products Administration – PRC [to 22 Jan 2022]

<http://english.nmpa.gov.cn/>

News

Over 2.95b COVID-19 vaccine doses administered on Chinese mainland

2022-01-21

More than 2.95 billion COVID-19 vaccine doses had been administered on the Chinese mainland as of Wednesday, data from the National Health Commission showed Thursday.

CCDC [Weekly Reports: Current Volume \(4\)](#)

2022-01-21 / No. 3

[View PDF of this issue](#)

Preplanned Studies: Prevalence, Incidence, and Characteristics of Tuberculosis Among Known Diabetes Patients — A Prospective Cohort Study in 10 Sites, 2013–2015

.....
.....
.....

Contents [click to move among sections]

Milestones - Perspectives

:: [Coronavirus \[COVID-19\] - WHO](#)

:: [Emergencies](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

.....
.....
.....

Organization Announcements

Editor's Note:

Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Airfinity [to 22 Jan 2022]

<https://www.airfinity.com/insights>

INSIGHTS & COMPANY NEWS

[COVID-19 vaccine market forecast to grow 29% to \\$84.9B in 2022, according to Airfinity](#)

Published by Airfinity

Jan 20, 2022

Airfinity forecasts the COVID-19 vaccine market is expected to reach \$65.6B in 2021 and grow to \$84.9B in 2022, a 29% growth. This excludes both the Chinese vaccines and market.

Our analysis predicts the 2022 market will be dominated by mRNA vaccines. Pfizer/BioNTech is expected to generate \$42.7B and Moderna \$25.7B. AstraZeneca is expected to be the third largest revenue generating vaccine with \$4.3B in revenue, followed by J&J with \$3.5B.

This would make the Pfizer/BioNTech and Moderna vaccine the two best selling medical products in 2022...

Paul G. Allen Frontiers Group [to 22 Jan 2022]

<https://alleninstitute.org/news-press/>

News

No new digest content identified.

BARDA – U.S. Department of HHS [to 22 Jan 2022]

<https://www.phe.gov/about/barda/Pages/default.aspx>

News

No new digest content identified.

BMGF - Gates Foundation [to 22 Jan 2022]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

Press release Jan 18, 2022

[Bill & Melinda Gates Foundation and Wellcome Pledge US\\$300 Million to CEPI for COVID-19 Pandemic Response and to Accelerate Epidemic Preparedness](#)

[See COVID Perspectives above for detail]

Bill & Melinda Gates Medical Research Institute [to 22 Jan 2022]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

No new digest content identified.

CARB-X [to 22 Jan 2022]

<https://carb-x.org/>

News

No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 22 Jan 2022]

<https://centerforvaccineethicsandpolicy.net/>

News/Analysis/Statements

:: Past weekly editions and posting of all segments of ***Vaccines and Global Health: The Week in Review*** are [available here](#).

:: **[Informed Consent: A Monthly Review – January 2022](#)** is now posted [here](#)

CEPI – Coalition for Epidemic Preparedness Innovations [to 22 Jan 2022]

<http://cepi.net/>

Latest News

[Bill & Melinda Gates Foundation and Wellcome pledge \\$300 million to CEPI to fight COVID-19 and combat threat of future pandemics](#)

New funding commitments will support CEPI's goal to condense new vaccine development timelines to 100 days, a third of the time it took to develop a COVID-19 vaccine.

COVID-19

19 Jan 2022

[See COVID Perspectives above for detail]

CEPI and Institut Pasteur de Dakar partner to advance COVID-19 vaccine manufacturing in Africa

In its initial phase, the new modular facility will manufacture up to 300 million doses of COVID-19 vaccine annually for use on the continent.

COVID-19

18 Jan 2022

[See COVID Perspectives above for detail]

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 22 Jan 2022]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 22 Jan 2022]

<https://dukeghic.org/>

Our Blog

No new digest content identified.

EDCTP [to 22 Jan 2022]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

20 January 2022

Call for expression of interest for Global Health EDCTP3 Joint Undertaking scientific committee

The Global Health EDCTP3 Joint Undertaking ([GH EDCTP3 JU](#)) has now opened a call for expression of interest for the selection of the members of its Scientific Committee.

The Global Health EDCTP3 Joint Undertaking (GH EDCTP3 JU) is a partnership between the European Union and the European and Developing Countries Clinical Trials Partnership (EDCTP) Association, whose members are several EU Member States and Associated countries and several African countries, and which builds on the first and second European and Developing Countries Clinical Trials Partnership (EDCTP) programmes...

18 January 2022

EDCTP mourns the loss of Dr Ricardo Pereira

On 11 January 2022, our dear colleague Dr Ricardo Pereira, Science Officer at the Portuguese Foundation for Science and Technology (FCT) and EDCTP General Assembly representative for Portugal, passed away following a long battle against cancer. Many in the EDCTP General Assembly, Scientific Advisory Committee and the Secretariat worked with him and knew him well. We are deeply saddened by this tragic news of his untimely passing.

Emory Vaccine Center [to 22 Jan 2022]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 22 Jan 2022]

<http://www.euvaccine.eu/>

Latest News, Events

No new digest content identified.

Fondation Mérieux [to 22 Jan 2022]

<http://www.fondation-merieux.org/>

News, Events

Support for Laboratories

LabMyNet Project Activities in Myanmar Build Diagnostic Capacity for HIV and SARS-CoV-2 Viral Load Surveillance

January 21, 2022, Myanmar

Renovation of the Medical Action in Myanmar laboratory, establishment of a molecular platform for HIV viral load, and training of ...

Publication

The Mérieux Foundation referent of an article published in The Lancet, resulting from an international research cooperation on Antimicrobial Resistance (AMR)

January 20, 2022, Global

Through TSARA project (an updated surveillance technique for resistance to antibiotics) in Madagascar, the Mérieux Foundation participated in a global ...

Unitaid

[to 22 Jan 2022]

<https://www.gavi.org/>

News Releases

No new digest content identified.

GHIT Fund [to 22 Jan 2022]

<https://www.ghitfund.org/newsroom/press>

No new digest content identified.

Global Fund [to 22 Jan 2022]

<https://www.theglobalfund.org/en/news/>

News & Stories

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 22 Jan 2022]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 22 Jan 2022]

<http://www.hillemanlabs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 22 Jan 2022]

<https://www.hhmi.org/news>

Press Room

Research Jan 21 2022

[These Scientists Are Racing to Beat Omicron](#)

As teams of researchers around the world race to piece together a picture of the Omicron variant, they're fast-tracking discoveries and transforming the way science is done.

Human Vaccines Project [to 22 Jan 2022]

<http://www.humanvaccinesproject.org/>

News

HVP COVID Report

Jan 20, 2022

[John Nkengasong: Lessons from Leading Africa's COVID-19 Response](#)

John Nkengasong, Ph.D.

Director, Africa Centres for Disease Control and Prevention

IAVI [to 22 Jan 2022]

<https://www.iavi.org/newsroom>

Latest News

January 18, 2022

[IAVI Welcomes Marion F. Gruber as Vice President, Public Health and Regulatory Science](#)

Regulatory and public health expertise will advance the development of and global access to innovative new solutions to important global health needs

NEW YORK – JANUARY 18, 2022 – IAVI is very pleased to announce the appointment of Marion F. Gruber, Ph.D., M.S., as Vice President, Public Health and Regulatory Science.

Dr. Gruber is a preeminent vaccine expert with 30 years of experience in the development and regulation of vaccines and related biologics. Most recently, she served as Director of the U.S. Food and Drug Administration (FDA) Office of Vaccine Research and Review, where she led the FDA's vaccine evaluation and licensure function and oversaw approval and authorization of vaccines for SARS-CoV-2, Zaire ebolavirus, and other global health challenges and emerging infectious disease threats...

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICRC [to 22 Jan 2022]

<https://www.icrc.org/en/whats-new>

Selected News Releases, Statements, Reports

No new digest content identified.

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 22 Jan 2022]

<http://media.ifrc.org/ifrc/news/press-releases/>

Selected Press Releases, Announcements

19/01/2022

[**WHO and IFRC partnership aims to build regional capacity in responding to key public health challenges**](#) [Middle East and North Africa]

Institut Pasteur [to 22 Jan 2022]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

IOM / International Organization for Migration [to 22 Jan 2022]

<http://www.iom.int/press-room/press-releases>

News - Selected

News

18 Jan 2022

[**Mongolia's Ban on Moving to Overcrowded Capital Hurt Migrants: IOM Research**](#)

News

18 Jan 2022

IOM and KSrelief Sign USD 20 Million Agreement to Help Yemen's Vulnerable Communities Needing Shelter, Clean Water and Sanitation

ISC / International Science Council [to 22 Jan 2022]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

News Blogs Podcasts

INGSA Horizons podcast hosts conversations on the science informing smart policy

19.01.2022

Six podcasts available now from the International Network for Government Science Advice (INGSA) explore the critical space between scientific evidence and policy decisions on topics such as cities, COVID-19, and societal transformation.

IVAC [to 22 Jan 2022]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 22 Jan 2022]

<http://www.ivi.int/>

IVI News & Announcements

IVI and SK bioscience Complete Recruitment for Phase III Clinical Trial of SKBS' COVID-19 Vaccine

:: Recruitment of global Phase III clinical trial of 'GBP510' completed, with vaccine expected to be authorized in the first half of 2022

:: A booster dose study is concurrently being planned to bring additional vaccine to the global COVID-19 vaccine market

January 19, 2022 SEOUL, Korea — The International Vaccine Institute (IVI) and SK bioscience announced on January 18 that they have completed the recruitment of participants for the Phase III global clinical trial of GBP510, SKBS' COVID-19 vaccine candidate. The Phase III clinical trial is the final stage of development to verify the safety and immunogenicity of the vaccine...

Johns Hopkins Center for Health Security [to 22 Jan 2022]

<https://www.centerforhealthsecurity.org/news/center-news/>

Center News

CommuniVax Coalition Launches Second Phase

Johns Hopkins Center for Health Security continues CommuniVax, a research coalition funded by the Chan Zuckerberg Initiative

January 22, 2021, Baltimore, MD – The Johns Hopkins Center for Health Security at the Johns Hopkins Bloomberg School of Public Health has received a new round of funding from the Chan Zuckerberg Initiative to continue support of the [CommuniVax](#) coalition. The purpose of the coalition is to strengthen community roles and involvement in equitable COVID-19 vaccination campaigns. The

project's second phase will focus on strengthening the relationships between communities of color and key local public health systems...

MSF/Médecins Sans Frontières [to 22 Jan 2022]

<http://www.msf.org/>

Latest [Selected Announcements]

Iraq

[The restless challenge of tackling COVID-19 in Iraq](#)

Project Update 21 Jan 2022

National Academy of Medicine - USA [to 22 Jan 2022]

<https://nam.edu/programs/>

Selected News/Programs/Events

[Expert Papers from the National Academy of Medicine Identify Lessons Learned and Compelling Needs for Health Product Manufacturers & Innovators and Digital Health After COVID-19](#)

January 18, 2022

WASHINGTON – In response to the devastating impact of COVID-19 on the American health system, the National Academy of Medicine (NAM) has convened experts in nine sectors of health, health care, and biomedical research to review how each sector responded to COVID-19, identify challenges encountered in combating the pandemic, and outline opportunities to reinforce, revitalize, and transform the health system including improving health equity for all. These insights are being released as nine NAM Perspectives discussion papers, and then bundled into a NAM Special Publication titled Emerging Stronger After COVID-19: Priorities for Health System Transformation, which is scheduled to be released in Spring 2022. The NAM Special Publication will include all nine previously published papers and a new concluding chapter that reviews cross-cutting themes and opportunities from the individual papers.

The final two papers in this series, focused on health product manufacturers and innovators and on digital health, were published January 18, 2022. [Health Product Manufacturers and Innovators COVID-19 Impact Assessment: Lessons Learned and Compelling Needs](#) focuses on the experience of organizations that research, develop, and manufacture products and services to support health and health care. The discussion paper focuses specifically on five product types: diagnostics, hospital equipment, medical devices, therapeutics, and vaccines...

National Academy of Sciences - USA [to 22 Jan 2022]

<http://www.nasonline.org/news-and-multimedia/>

News

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 22 Jan 2022]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

National Vaccine Advisory Committee [NVAC] 2022 Meetings
[February 10-11, 2022](#)

NIH [to 22 Jan 2022]

<http://www.nih.gov/news-events/news-releases>

News Releases

Researchers highlight COVID-19 neurological symptoms and need for rigorous studies

January 20, 2022 — Scientists explain the importance of increased research into the underlying causes of Long Covid and possible ways to treat its symptoms.

COVID-19 vaccination does not reduce chances of conception, study suggests

January 20, 2022 — NIH-funded research shows infection can affect male fertility.

SARS-CoV-2 may cause fetal inflammation even in the absence of placental infection

January 18, 2022 — Small NIH study contributes to understanding of COVID-19 during pregnancy.

OECD [to 22 Jan 2022]

<http://www.oecd.org/newsroom/publicationsdocuments/bydate/>

Newsroom

No new digest content identified.

PATH [to 22 Jan 2022]

<https://www.path.org/media-center/>

Press Releases

PATH appoints Meïssa Diaw as Chief People and Diversity Officer

January 20, 2022 by PATH

Seattle, WA - [Meïssa Diaw](#), formerly Human Resources Director for Africa, is taking on new responsibilities at PATH to serve as the organization's first Africa-based Chief People and Diversity Officer. Based in Senegal, he will direct PATH's global HR functions and lead an empowered team of HR specialists across Asia, Africa, and North America...

Sabin Vaccine Institute [to 22 Jan 2022]

<http://www.sabin.org/updates/pressreleases>

Statements and Press Releases

No new digest content identified.

UNAIDS [to 22 Jan 2022]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

8 January 2022

Empowering people who inject drugs in Uganda

17 January 2022

Pre-exposure prophylaxis use expands, but not fast enough

UNHCR Office of the United Nations High Commissioner for Refugees [to 22 Jan 2022]

<http://www.unhcr.org/en-us/media-centre.html>

Selected News Releases, Announcements

No new digest content identified.

UNICEF [to 22 Jan 2022]

<https://www.unicef.org/media/press-releases>

Press Releases, News Notes, Statements [Selected]

News note

01/18/2022

UNICEF enters supply agreements for COVID-19 oral antiviral medicine Molnupiravir

NEW YORK/COPENHAGEN, 18 January 2022 – UNICEF has signed several long term agreements (LTA) with suppliers for the procurement of the new antiviral medicine Molnupiravir.

UNICEF procurement of Molnupiravir is dependent on clinical recommendations, regulatory approvals and compliance with UNICEF quality assurance requirements. In December, the US Food and drug administration issued an emergency use authorization for the use of Molnupiravir in the treatment of COVID19 in certain patients. Molnupiravir is currently under assessment by WHO.

These agreements will help ensure that low and middle-income countries (LMICs) have timely access to novel COVID-19 therapies. UNICEF will continue to work with ACT-A (Access to COVID-19 Tools Accelerator) partners and industry to ensure supply availability, achieve affordable prices and capacity to meet country needs. Supply will also be available for ACT-A partners wishing to deploy Molnupiravir in countries.

UNICEF will work closely with other ACT-A partners such as WHO, the Global Fund and Unitaid to ensure an equitable access to supply for LMICs.

Unitaid [to 22 Jan 2022]

<https://unitaid.org/>

Featured News

No new digest content identified.

USAID [to 22 Jan 2022]

<https://www.usaid.gov/news-information/press-releases/2021>

Selected Press Releases, Statements, Announcements

News

No new digest content identified.

Vaccine Equity Cooperative [nee Initiative] [to 22 Jan 2022]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 22 Jan 2022]

<https://www.vaccineacceptance.org/>

Announcements

No new digest content identified.

Vaccine Confidence Project [to 22 Jan 2022]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 22 Jan 2022]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

No new digest content identified.

Wellcome Trust [to 22 Jan 2022]

<https://wellcome.ac.uk/news>

News. Opinion, Reports

News

[\\$300 million invested in vaccine innovations to end Covid-19 and prevent future epidemics](#)

19 January 2022

Wellcome and the Bill & Melinda Gates Foundation have both pledged \$150 million each to the Coalition for Epidemic Preparedness Innovations (CEPI) to help end the Covid-19 pandemic and prevent another major outbreak.

The Wistar Institute [to 22 Jan 2022]

<https://www.wistar.org/news/press-releases>

Press Releases

Jan. 17, 2022

[Wistar Scientists Identify Therapeutic Target for Epstein-Barr Virus](#)

They found that EBV uses some of the same proteins as the host cell to express itself, and one of the proteins is already targeted by an existing drug.

WFPHA: World Federation of Public Health Associations [to 22 Jan 2022]

<https://www.wfpgha.org/>

Latest News - Blog

[Letter from the World Federation of Public Health Associations \(WFPHA\) on behalf of the Sustainable Health Equity Movement \(SHEM\) to the Executive Board of the World Health Organization \(EB-WHO\). 24-29 January 2022](#)

...WFPHA and SHEM ask the EB-WHO to bring the following proposals to the WHA:

1) Aligned with the Multilateral Leaders Task Force on COVID-19 Vaccines, Therapeutics and Diagnostics, **WHO Member States must implement an equitable distribution of vaccines against COVID-19, which presupposes patent wavering, the sharing of knowledge and the transfer of technology, enabling the expansion of production and distribution based on**

ethical and epidemiological criteria, at no cost to the end consumer. This must be combined with the WHO's decisive support to vaccine production initiatives for patent pooling and technology transfer contributing to global equity Covid vaccine coverage.

2) The WHA must agree to develop and, on an accelerated timeline, negotiate and adopt a new Pandemic Treaty that, in addition to improving global preparedness and response to health emergencies, helps all countries – especially low- and middle-income – to strengthen their national health systems to ensure everyone's right to health. The Treaty must also consider the social determinants of health, contemplating intersectoral measures around social, environmental, and economic responses to support health actions.

3) The WHA must recognize that COVID-19 is more than a pandemic and is best characterized as a syndemic. The world suffers from the synergy of COVID-19 and other communicable and non-communicable diseases with political, economic, and environmental macro-processes that jointly cause deep changes that favor the emergence of zoonoses, and which reflect and generate social inequalities and inequities among and within countries. The construction of a “new normal”, better and fairer than the one that brought us here, requires facing all the dimensions of this complex reality, where the global unfair economic order must be faced and the right to development can be achieved by all nations and peoples...

World Bank [to 22 Jan 2022]

<http://www.worldbank.org/en/news/all>

Selected News, Announcements

South Africa's Covid-19 Response Gets a \$750 Million Boost

WASHINGTON, January 20, 2022 —The World Bank Group Board of Executive Directors today approved South Africa's request for a \$750 million development policy loan (DPL). This loan will support the Government...

Date: January 21, 2022 Type: Press Release

Transcript: Exceptional Uncertainty and the Global Economy: A Conversation with David Malpass and Adam Posen

You can watch a replay of the event here. MR. ADAM POSEN: It is my honor and pleasure to be hosting a conversation with David Malpass, the 13th President of the World Bank Group. And I will...

Date: January 19, 2022 Type: Speeches and Transcripts

World Organisation for Animal Health (OIE) [to 22 Jan 2022]

<https://www.oie.int/en/media/news/>

Press Releases, Statements

No new digest content identified.

WTO - World Trade Organisation [to 22 Jan 2022]

http://www.wto.org/english/news_e/news_e.htm

WTO News and Events

DG Okonjo-Iweala calls on ministers to step up negotiating efforts, harvest outcomes

21 January 2022

Director-General Ngozi Okonjo-Iweala on 21 January called on ministers from a cross-section of WTO members to push ahead in all ongoing negotiations, and work with “pragmatism, creativity, and

flexibility” to harvest agreements as and when they are within reach. Ministers broadly accepted her suggestion to accelerate work, both in Geneva and in capitals, so WTO members can deliver results despite the uncertainty regarding the rescheduling of the 12th Ministerial Conference (MC12) following its Omicron-induced postponement in November.

The informal gathering of around 30 trade ministers is traditionally hosted by the Swiss government in Davos but was held virtually this year in line with the World Economic Forum's decision to cancel its in-person annual meeting.

In her remarks to the event, the Director-General noted that pandemic-related uncertainty would continue to prevail so long as large numbers of people in much of the world remained unvaccinated against COVID-19 – and that the WTO had a contribution to make in ending vaccine inequity. She said that while the desire to hold an in-person MC12 was widely shared, the changing epidemiological conditions made it difficult to set a date at this time. This does not rule out reassessing and fixing a date at a more propitious time since there was clearly a desire on the part of members to schedule a physical ministerial at some point...

The Director-General called ministers' attention to the key sticking points on the WTO's response to the pandemic, fisheries subsidies and agriculture, while also making the case for moving ahead with WTO reform, including dispute settlement.

In their interventions, many ministers said that while they want to hold MC12 when circumstances permit, they would be prepared to continue work in all areas in the interim and conclude negotiations where achievable. **As countries seek to promote recovery from the social and economic consequences of the pandemic, many highlighted the importance of ensuring adequate access to medical products, including vaccines.** A number of ministers said the negotiations on pandemic response and fisheries subsidies should be concluded as soon as possible...

WTO report looks into steps taken to boost LDCs' participation in international trade

19 January 2022

A new WTO publication launched on 19 January highlights that further support will be needed from the international community in the next decade to strengthen least-developed countries' (LDC) participation in world trade. While LDCs have benefited over the past ten years from greater market access opportunities, flexibilities in implementing WTO rules and trade-related technical assistance, the COVID-19 pandemic has led to even greater challenges for these countries, hitting their exports hard.

.....

ARM [Alliance for Regenerative Medicine] [to 22 Jan 2022]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 22 Jan 2022]

<https://www.bio.org/press-releases>

Press Releases, Letters, Testimony, Comments [Selected]

No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 22 Jan 2022]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 22 Jan 2022]

<https://internationalbiotech.org/news/>

News

No new digest content identified.

IFPMA [to 22 Jan 2022]

<http://www.ifpma.org/resources/news-releases/>

Selected Press Releases, Statements, Publications

[11 billion COVID-19 vaccines produced in 2021 has resulted in the biggest immunization campaign in human history and 2022 will require more and better vaccine redistribution and innovation](#)

16 December 2021

[See COVID Perspectives above for detail]

[A timely reality check on silent pandemic of antimicrobial resistance](#)

20 January 2022

The scale and threat of antimicrobial resistance is much bigger and more imminent than previously anticipated. New evidence shows that, in 2019, the global burden associated with drug-resistant infections was an estimated 4.95 million deaths, of which AMR was the direct cause of at least 1.27 million deaths. This number is only set to grow further, unless action is taken. The direction of travel is not downwards, with COVID-19 further fuelling the issue of AMR, leaving us on the course of 10 million deaths per year by 2050...

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

[GENEZIS, the Serbian and Montenegrin Generic and Biosimilar Medicines Association, joins IGBA \(January 2022\)](#)

IGBA, the International Generic and Biosimilar medicines Association, representing global manufacturers of generic and biosimilar medicines, announced today that GENEZIS has been accepted and welcomed as a new IGBA Associate Member.

International Alliance of Patients' Organizations – IAPO [to 22 Jan 2022]

<https://www.iapo.org.uk/news/topic/6>

Press and media [Selected]

No new digest content identified.

PhRMA [to 22 Jan 2022]
<http://www.phrma.org/>
Latest News [Selected]
No new digest content identified.

* * * *

Contents [click to move among sections]

::
*Milestones - **Perspectives***
:: *Coronavirus [COVID-19] - WHO*
:: *Emergencies*
:: *Organization Announcements*
:: *Journal Watch*

* * * *

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 12, 2020 Issue 4
<https://www.tandfonline.com/toc/uabr21/current>
[Reviewed earlier]

AMA Journal of Ethics

Volume 24, Number 1: E1-105 Jan 2022
<https://journalofethics.ama-assn.org/issue/inequity-along-medicaldental-divide>

Inequity Along the Medical/Dental Divide

Dental and medical health systems in the United States have evolved as fully separate entities. This division exacerbates health inequity, since patients' poor oral health affects their general health. The professionally entrenched view that what's in patients' mouths is somehow isolated from what's going on in the rest of their bodies is one all clinicians need to resist, since this view can be a source of harm, particularly among vulnerable patients and communities. Practical and ethical strategies for better aligning medical and dental goals of care are considered in this issue.

American Journal of Infection Control

January 2022 Volume 50 Issue 1 p1-122

<http://www.ajicjournal.org/current>

Major Articles

[Reviewed earlier]

American Journal of Preventive Medicine

February 2022 Volume 62 Issue 2 p149-306

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

January 2022 112(1)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 105 (2021): Issue 6 (Dec 2021)

<https://www.ajtmh.org/view/journals/tpmd/105/6/tpmd.105.issue-6.xml>

[Reviewed earlier]

Annals of Internal Medicine

January 2022 Volume 175, Issue 1

<http://annals.org/aim/issue>

Original Research

Influenza Vaccine Uptake and Missed Opportunities Among the Medicare-Covered Population With High-Risk Conditions During the 2018 to 2019 Influenza Season: A Retrospective Cohort Study

Bo-Hyun Cho, PhD, Cindy Weinbaum, MD, MPH, Yuping Tsai, PhD, Ram Koppaka, MD, PhD

Special Articles

Update on and Future Directions for Use of Anti-SARS-CoV-2 Antibodies: National Institutes of Health Summit on Treatment and Prevention of COVID-19

FREE

César Boggiano, PhD, Robert W. Eisinger, PhD, Andrea M. Lerner, MD, James M. Anderson, MD, PhD, ... et al.

Pages:119–126

Artificial Intelligence – An International Journal

Volume 302 January 2022

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/302/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 22 Jan 2022)

[No new digest content identified]

BMJ Global Health

January 2022 - Volume 7 - 1

<https://gh.bmj.com/content/7/1>

[Reviewed earlier]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 22 Jan 2022)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 22 Jan 2022)

[Low incidence of COVID-19 case severity and mortality in Africa; Could malaria co-infection provide the missing link?](#)

Despite reports of malaria and coronavirus diseases 2019 (COVID-19) co-infection, malaria-endemic regions have so far recorded fewer cases of COVID-19 and deaths from COVID-19, indicating a probable protection...

Authors: Silas Acheampong Osei, Robert Peter Biney, Alberta Serwah Anning, Lydia Nkuah Nortey and George Gharthey-Kwansah

Citation: BMC Infectious Diseases 2022 22:78

Content type: Research

Published on: 22 January 2022

[Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination \(SerOzNET\)](#)

Cancer is associated with excess morbidity and mortality from coronavirus disease 2019 (COVID-19) following infection by the novel pandemic coronavirus SARS-CoV-2. Vaccinations against SARS-CoV-2 have been rap...

Authors: Amy Body, Elizabeth Ahern, Luxi Lal, Karen Gillett, Hesham Abdulla, Stephen Opat, Tracey O'Brien, Peter Downie, Stuart Turville, C. Mee Ling Munier, Corey Smith, C. Raina MacIntyre and Eva Segelov

Citation: BMC Infectious Diseases 2022 22:70

Content type: Study protocol

Published on: 20 January 2022

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 22 Jan 2022)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 22 Jan 2022)

[Humoral immune response after different SARS-CoV-2 vaccination regimens](#)

The humoral immune response after primary immunisation with a SARS-CoV-2 vector vaccine (AstraZeneca AZD1222, ChAdOx1 nCoV-19, Vaxzevria) followed by an mRNA vaccine boost (Pfizer/BioNTech, BNT162b2; Moderna, ...

Authors: Ruben Rose, Franziska Neumann, Olaf Grobe, Thomas Lorentz, Helmut Fickenscher and Andi Krumbholz

Citation: BMC Medicine 2022 20:31

Content type: Research article

Published on: 21 January 2022

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 22 Jan 2022)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 22 Jan 2022)

[COVID-19 myth-busting: an experimental study](#)

COVID-19 misinformation is a danger to public health. A range of formats are used by health campaigns to correct beliefs but data on their effectiveness is limited. We aimed to identify A) whether three common...

Authors: Aimée Challenger, Petroc Sumner and Lewis Bott

Citation: BMC Public Health 2022 22:131

Content type: Research article

Published on: 19 January 2022

[Knowledge, attitudes, and perceptions of COVID-19 vaccine and refusal to receive COVID-19 vaccine among healthcare workers in northeastern Ethiopia](#)

Major efforts are being made to control the spread and impacts of the coronavirus pandemic using vaccines. Ethiopia began on March 13, 2021, to vaccinate healthcare workers (HCWs) for COVID-19 with the AstraZe...

Authors: Metadel Adane, Ayeche Ademas and Helmut Kloos

Citation: BMC Public Health 2022 22:128

Content type: Research

Published on: 18 January 2022

Association between COVID-19 vaccine hesitancy and generalized trust, depression, generalized anxiety, and fear of COVID-19

Although numerous studies have been published on the predictors of COVID-19 vaccine hesitancy, some possible predictors remain underexplored. In this study, we explored the associations of unwillingness and in...

Authors: Yoichi Sekizawa, Sora Hashimoto, Kenzo Denda, Sae Ochi and Mirai So

Citation: BMC Public Health 2022 22:126

Content type: Research

Published on: 18 January 2022

Examining COVID-19 vaccine uptake and attitudes among 2SLGBTQ+ youth experiencing homelessness

The COVID-19 pandemic has disproportionately impacted 2SLGBTQ+ youth experiencing homelessness. Little is known about vaccine attitudes and uptake among this population. To address this, the objectives of this...

Authors: Alex Abramovich, Nelson Pang, Sharumathy Kunasekaran, Amanda Moss, Tara Kiran and Andrew D. Pinto

Citation: BMC Public Health 2022 22:122

Content type: Research

Published on: 18 January 2022

Vaccination against influenza among Lebanese health care workers in the era of coronavirus disease 2019

Health-care workers (HCWs) are at a higher occupational risk of contracting and transmitting influenza. Annual vaccination is an essential tool to prevent seasonal influenza infection. However, HCWs vaccine he...

Authors: Dalal Youssef, Atika Berry, Janet Youssef and Linda Abou-Abbas

Citation: BMC Public Health 2022 22:120

Content type: Research

Published on: 18 January 2022

BMC Research Notes

<http://www.biomedcentral.com/bmcresearchnotes/content>

(Accessed 22 Jan 2022)

[No new digest content identified]

BMJ Evidence-Based Medicine

February 2022 - Volume 27 - 1

<https://ebm.bmj.com/content/27/1>

Evidence synthesis

Effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review (1 October, 2020) Free

David Jarrom, Lauren Elston, Jennifer Washington, Matthew Prettyjohns, Kimberley Cann, Susan Myles, Peter Groves

BMJ Open

January 2022 - Volume 12 - 1

<https://bmjopen.bmj.com/content/12/1>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 100(1); 2022 Jan 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/397045/>

[Reviewed earlier]

Cell

Jan 20, 2022 Volume 185 Issue 2 p221-400

<https://www.cell.com/cell/current>

[New issue; No digest content identified]

Child Care, Health and Development

Volume 48, Issue 1 Pages: 1-175 January 2022

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 111, Issue 1 Pages: 1-331 January 2022

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

December 2021 Volume 43 Issue 12 p2041-2172

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 18 Issue 6, December 2021

<https://journals.sagepub.com/toc/ctja/18/6>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 22 Jan 2022]

[No new digest content identified]

Contemporary Clinical Trials

Volume 112 January 2022

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/112/suppl/C>

[No new digest content identified]

The CRISPR Journal

Volume 4, Issue 6 / December 2021

<https://www.liebertpub.com/toc/crispr/4/6>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 9, issue 4, December 2021

<https://link.springer.com/journal/40142/volumes-and-issues/9-4>

[Reviewed earlier]

Current Opinion in Infectious Diseases

February 2022 - Volume 35 - Issue 1

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

Volume 108, Issue 1 December 2020

<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>

[Reviewed earlier]

Developing World Bioethics

Volume 21, Issue 4 Pages: 149-238 December 2021

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 31, Issue 8, 2021

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 15 - Issue 5 - October 2021

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 46, Issue 1 Pages: 1-298 January 2022

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

EMBO Reports

Volume 23 Issue 1 5 January 2022

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 28, Number 1—January 2022

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 37 December 2021

<https://www.sciencedirect.com/journal/epidemics/vol/37/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 149 - 2021

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 44, Issue 1 Pages: 1-39 January–February 2022

<https://onlinelibrary.wiley.com/toc/25782363/current>

Articles Open Access

[The Ethical Implications of Big Data Research in Public Health: “Big Data Ethics by Design” in the UK-REACH Study](#)

Ruby Reed-Berendt, Edward S. Dove, Manish Pareek, on behalf of the UK-REACH Study Collaborative Group

Pages: 2-17

First Published: 22 December 2021

Articles

[Biobank Participants’ Attitudes toward Requiring Understanding for Biobank Consent](#)

T.J. Kasperbauer, Colin Halverson, Abigail Garcia, Karen K. Schmidt, Peter H. Schwartz

Pages: 18-28

First Published: 22 December 2021

Research Documents for Populations with Limited English Proficiency: Translation Approaches Matter

Sonia Colina, Miriam Rodríguez-Guerra, Nicole Marrone, Maia Ingram, Karla J. Navarro, Genesis Arizmendi, Laura Coco

Pages: 29-39

First Published: 22 December 2021

Ethics & International Affairs

Fall 2021 (35.3) | October 2021

<https://www.ethicsandinternationalaffairs.org/2021/fall-2021-35-3/>

The editors of Ethics & International Affairs are pleased to present the Fall 2021 issue of the journal! The highlight of this issue is a book symposium organized by Peter Balint on Ned Dobos's Ethics, Security, and the War Machine, featuring contributions by Peter Balint; Neta C. Crawford; C. A. J. Coady; Ned Dobos; Cécile Fabre; Christopher J. Finlay; David Rodin; and Cheyney Ryan. Additionally, the issue includes a feature article by Philipp Gisbertz-Astolfi on the reduced legal equality of combatants in war and an essay by Hendrik Schopmans and Jelena Cupać on ethical AI, gender equality, and illiberal backlash politics. It also contains a review essay by Andreas Papamichail on the global politics of health security, and a book review by Claire Finkelstein.

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 19 December 2021

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/19/suppl/C>

[Reviewed earlier]

The European Journal of Public Health

Volume 31, Issue 6, December 2021

<https://academic.oup.com/eurpub/issue/31/6>

[Reviewed earlier]

Expert Review of Vaccines

Vol 20 (12) 2021

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Forum for Development Studies

Volume 48, 2021 - Issue 3

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 22 Jan 2022]
[No new digest content identified]

Global Health Action

Volume 14, Issue 1 (2021)
<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>
[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 9, No. 4 December 31, 2021
<http://www.ghspjournal.org/content/current>
[Reviewed earlier]

Global Legal Monitor – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>
[Accessed 22 Jan 2022]
[No new digest content identified]

Global Public Health

Volume 17, Issue 1 (2022)
<http://www.tandfonline.com/toc/rgph20/current>
[New issue; No digest content identified]

Globalization and Health

<http://www.globalizationandhealth.com/>
[Accessed 22 Jan 2022]

[Global research activity on mathematical modeling of transmission and control of 23 selected infectious disease outbreak](#)

Mathematical analysis and modeling allow policymakers to understand and predict the dynamics of an infectious disease under several different scenarios. The current study aimed to analyze global research activity on mathematical modeling of transmission and control of several infectious diseases with a known history of serious outbreaks.

Authors: Waleed M. Sweileh

Content type: Research

21 January 2022

Health and Human Rights

Volume 23, Issue 2, December 2021
<https://www.hhrjournal.org/volume-23-issue-2-december-2021/>
[Reviewed earlier]

Health Economics, Policy and Law

Volume 17 - Special Issue 1 - January 2022

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

SPECIAL ISSUE: Country Responses to the COVID-19 Pandemic

Articles analyzing country responses in Australia, New Zealand, Canada, U.S., Belgium, Netherlands, Sweden, France, Italy

Health Policy and Planning

Volume 36, Issue 10, December 2021

<https://academic.oup.com/heapol/issue/36/10>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 22 Jan 2022]

[No new digest content identified]

Human Gene Therapy

Volume 33, Issue 1-2 / January 2022

<https://www.liebertpub.com/toc/hum/33/1-2>

Review Free

[An Overview of Cell and Gene Therapy Development in China](#)

Yitong Wang, Tingting Qiu, Shuyao Liang, and Mondher Toumi

Pages:14–24

Published Online:6 September 2021

<https://doi.org/10.1089/hum.2021.126>

Abstract

China, the first country worldwide to approve a gene therapy in 2003, almost lost the advantage for a head start in cell and gene therapy (CGT) development due to a lack of clear and strict regulatory frameworks. The rapid advancements of CGTs' development worldwide as well as their therapeutic potential have triggered the government to conduct a spate of regulatory reforms to promote normative development of CGTs in China. Encouraged by policy support, the remarkable progress for CGTs in China has been observed over the past few years, thereby catapulting China back into the forefront of CGTs worldwide. This article aims to provide an overview of regulatory reforms, the current development landscape of CGTs, as well as key contributors and challenges for CGT development in China.

Humanitarian Exchange Magazine

Number 79, May 2021

<https://odihpn.org/magazine/localisation-and-local-humanitarian-action/>

[Localisation and local humanitarian action](#)

by HPN October 2020

The theme of this edition of *Humanitarian Exchange* is localisation+ and local humanitarian action. Five years ago this week, donors, United Nations (UN) agencies, non-governmental organisations (NGOs),

the International Committee of the Red Cross (ICRC) and International Federation of Red Cross and Red Crescent Societies (IFRC) committed within the Grand Bargain to increase multi-year investments in the institutional capacities of local and national responders, and to provide at least 25% of humanitarian funding to them as directly as possible. Since then, there is increasing consensus at policy and normative level, underscored by the Covid-19 pandemic, that local leadership should be supported. Localisation has gone from a fringe conversation among policy-makers and aid agencies in 2016 to a formal priority under the Grand Bargain. Wider global movements on anti-racism and decolonisation have also brought new momentum to critical reflections on where power, knowledge and capacity reside in the humanitarian system. Yet progress has been slow and major gaps remain between the rhetoric around humanitarian partnerships, funding and coordination and practices on the ground.

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 17, Issue 10, 2021

<https://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

Immunity

Jan 11, 2022 Volume 55 Issue 1 p1-184

<https://www.cell.com/immunity/current>

[New issue; No digest content identified]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 22 Jan 2022]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>

[Accessed 22 Jan 2022]

[No new digest content identified]

International Health

Volume 13, Issue 6, November 2021

<https://academic.oup.com/inthealth/issue/13/6>

[Reviewed earlier]

International Human Rights Law Review

Volume 10 (2021): Issue 2 (Dec 2021)

<https://brill.com/view/journals/hrlr/10/2/hrlr.10.issue-2.xml>

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol 9, No 1 (2022) January 2022

<https://www.ijcmph.com/index.php/ijcmph/issue/view/84>

[Reviewed earlier]

International Journal of Epidemiology

Volume 50, Issue 6, December 2021

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 14 Issue 5 2021

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/5>

Table of Contents

[Reviewed earlier]

International Journal of Infectious Diseases

January 2022 Volume 114 p1-278

<https://www.ijidonline.com/current>

[Reviewed earlier]

JAMA

January 18, 2022, Vol 327, No. 3, Pages 199-294

<https://jamanetwork.com/journals/jama/currentissue>

Research Letter

[Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals](#)

Brian Grunau, MD, MHSc; David M. Goldfarb, MD; Michael Asamoah-Boaheng, MPhil; et al.

free access has active quiz

JAMA. 2022;327(3):279-281. doi:10.1001/jama.2021.21921

This study investigates the immunogenicity of extended mRNA vaccine dosing intervals.

[Multisystem Inflammatory Syndrome in Children by COVID-19 Vaccination Status of Adolescents in France](#)

Michael Levy, MD, PhD; Morgan Recher, MD, PhD; Hervé Hubert, MD, PhD; et al.

free access has active quiz

JAMA. 2022;327(3):281-283. doi:10.1001/jama.2021.23262

This study examines the risk of multisystem inflammatory syndrome in children among those aged 12 years or older by COVID-19 vaccination status during September 2021 and October 2021 in France.

Viewpoint

[A National Strategy for the "New Normal" of Life With COVID](#)

Ezekiel J. Emanuel, MD, PhD; Michael Osterholm, PhD, MPH; Celine R. Gounder, MD, ScM

free access has multimedia has audio

JAMA. 2022;327(3):211-212. doi:10.1001/jama.2021.24282

This Viewpoint discusses how US policy makers should address how the nation can move forward as the pandemic persists.

[A National Strategy for COVID-19 Testing, Surveillance, and Mitigation Strategies](#)

David Michaels, PhD, MPH; Ezekiel J. Emanuel, MD, PhD; Rick A. Bright, PhD

free access has multimedia has audio

JAMA. 2022;327(3):213-214. doi:10.1001/jama.2021.24168

This Viewpoint discusses the areas on which the US needs to improve its public health infrastructure in order to reduce COVID-19 transmission and achieve a “new normal”: testing, surveillance, masking, and ventilation.

[A National Strategy for COVID-19 Medical Countermeasures Vaccines and Therapeutics](#)

Luciana L. Borio, MD; Rick A. Bright, PhD; Ezekiel J. Emanuel, MD, PhD

free access has multimedia has audio

JAMA. 2022;327(3):215-216. doi:10.1001/jama.2021.24165

This Viewpoint proposes a multistep plan that US can implement to achieve a “new normal” of living, in which the combined risk of all viral respiratory illnesses, including COVID-19, does not exceed the risk during prepandemic years.

[The First 2 Years of COVID-19 Lessons to Improve Preparedness for the Next Pandemic](#)

Jennifer B. Nuzzo, DrPH, SM; Lawrence O. Gostin, JD

free access

JAMA. 2022;327(3):217-218. doi:10.1001/jama.2021.24394

This Viewpoint examines the lessons that the COVID-19 pandemic can provide public health institutions and health care personnel to advance preparedness, detection, and response regarding future pandemics.

[The Pandemic Preparedness Program Reimagining Public Health](#)

Eli Y. Adashi, MD, MS; I. Glenn Cohen, JD

free access

JAMA. 2022;327(3):219-220. doi:10.1001/jama.2021.23656

This Viewpoint reviews the leading objectives of the pandemic preparedness proposal, discusses the outcome of comparable past federal efforts, and emphasizes the imperative of intragovernmental coordination.

JAMA Network

[COVID-19 Update January 22, 2022](#)

These articles on COVID-19 were published across the JAMA Network in the last week.

JAMA Pediatrics

January 2022, Vol 176, No. 1, Pages 7-108

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JBİ Evidence Synthesis

December 2021 - Volume 19 - Issue 12

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

January 2022 Volume 70 Issue 1 p1-170

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 73 (2022)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

Journal of Community Health

Volume 46, issue 6, December 2021

<https://link.springer.com/journal/10900/volumes-and-issues/46-6>

[Reviewed earlier]

Journal of Development Economics

Volume 154 January 2022

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/154/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 17 Issue 1-2, February-April 2022

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

January 2022 - Volume 76 - 1

<https://jech.bmj.com/content/76/1>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 14, Issue 4 Pages: 257-345 December 2021

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 17, Issue 2, 2021

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 32, Number 4, November 2021

<https://muse.jhu.edu/issue/46802>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 23, issue 6, December 2021

<https://link.springer.com/journal/10903/volumes-and-issues/23-6>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 19, 2021_ Issue 4

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 224, Issue 6, 15 September 2021

<https://academic.oup.com/jid/issue/224/6>

[Reviewed earlier]

Journal of Medical Ethics

January 2022 - Volume 48 - 1

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 8, Issue 4 (2021)

<https://digitalrepository.aurorahealthcare.org/jpcrr/>

Cancer Screening

[Reviewed earlier]

Journal of Pediatrics

January 2022 Volume 240 p1-324

<http://www.jpeds.com/current>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

<https://joppp.biomedcentral.com/>

[Accessed 22 Jan 2022]

[No new digest content identified]

Journal of Public Health Management & Practice

January/February 2022 - Volume 28 - Issue 1

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 42, issue 4, December 2021

<https://link.springer.com/journal/41271/volumes-and-issues/42-4>

[Reviewed earlier]

Journal of Refugee & Global Health

Volume 4, Issue 1 (2021)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

Journal of the Royal Society – Interface

January 2022 Volume 19 Issue 186

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 29, Issue 1, January 2022

<https://academic.oup.com/jtm/issue>

Editor's Choice

[A disease severity scale for the evaluation of vaccine and other preventive or therapeutic interventions for travellers' diarrhoea](#)

Nicole Maier, PhD, Mark S Riddle, MD, DrPH, Ramiro Gutiérrez, MD, Jamie A Fraser, MPH, Patrick Connor, MD ...

Journal of Travel Medicine, Volume 29, Issue 1, January 2022, taab139,

<https://doi.org/10.1093/jtm/taab139>

Journal of Virology

Volume 96 Number 1 January 2022

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Jan 22, 2022 Volume 399 Number 10322 p335-410

<https://www.thelancet.com/journals/lancet/issue/current>

Editorial

Antimicrobial resistance: time to repurpose the Global Fund

The Lancet

Antimicrobial resistance (AMR) is a major cause of death globally, with a burden likely to be higher than that of HIV or malaria, according to the most comprehensive assessment of bacterial AMR to date published in The Lancet. The data presented in this analysis are striking: in 2019, the deaths of 4·95 million people were associated with drug-resistant bacterial infections. 1·27 million deaths were directly caused by AMR. For the first time, the study provides estimates for 204 countries and territories, as well as data for the regional impacts of AMR. This study also reports details of AMR burden for 23 bacterial pathogens—*Escherichia coli* is accountable for the most deaths—and 88 pathogen–drug combinations, with methicillin-resistant *Staphylococcus aureus* causing the highest number of deaths. These new findings are pivotal to inform location-specific policy decisions and clinical practice.

The threat of AMR has long been signalled. And the steps needed to tackle AMR—boosting public awareness, better surveillance, improved diagnostics, more rational use of antibiotics, access to clean water and sanitation, embracing One Health, and investments in new antimicrobials and vaccines—have been consistently recommended in reports such as The Lancet Infectious Diseases Commission on Antibiotic Resistance in 2013 and the O'Neill report in 2016. There have been some noteworthy responses during the past decade. The Global Antimicrobial Resistance and Use Surveillance System was launched by WHO in 2015. The Fleming Fund (an aid programme supporting 24 countries across Africa and Asia to tackle AMR) was established in 2015. In December, 2021, G7 Finance Ministers issued statements to support antibiotic development.

But action has been episodic and uneven, resulting in global inequities in AMR. Sub-Saharan Africa and south Asia have the highest burden of AMR according to the new study, likely driven by high infection rates and a lack of access to antibiotics, compounded by serious data gaps. Innovation has been extremely slow. Vaccines are available for only one of the six leading pathogens described in the study. The clinical pipeline for antibiotics is too small to tackle the increasing emergence and spread of AMR. A lot of research has described the problem of AMR, but not enough has been done to study the solutions or how to change the political conversation.

National leaders now have an obligation to move AMR to a higher position in their political agendas. Research efforts should be accelerated to address knowledge and innovation gaps and to inform policy and practices. Access to effective antibiotics must be ensured. Above all, AMR must be seen as a global issue, which needs a globally coherent plan with a One Health approach. AMR has too often been viewed as an abstract risk to health, a potential cause of illness and death at some point in the future. This way of thinking makes it easy to ignore. But the new comprehensive estimates show that AMR is killing large numbers of people now. The harms of AMR are with us today. The COVID-19 pandemic could even accelerate the problem of AMR due to antibiotic misuse and prolonged hospital stays. This fact demands that actions to address AMR be scaled up urgently.

One immediate opportunity must be seized. Later this year, The Global Fund to Fight AIDS, Tuberculosis and Malaria will hold its Seventh Replenishment meeting. The focus for inviting donor

investment is likely to remain on the three diseases that have been the hallmark of its success. However, the Fund is actively considering how to broaden its remit in response to a very different global context—notably, the need for further measures to strengthen pandemic preparedness and create resilient health systems in an era of climate crisis. 2022 is also the 20th anniversary of The Global Fund's inception. Now is the right moment to review its fundamental purpose. The Fund was established to invest in programmes to end the infectious diseases that cause the greatest burden of illness and death, especially in low-income and middle-income countries. It has proven itself a highly effective instrument for protecting susceptible populations from preventable and treatable diseases. The existing burden of AMR and its future threat should be an urgent stimulus to revise and widen The Global Fund's mission. It is now time for the Fund to embrace AMR as one of its core responsibilities. And donors should invest generously in such a renewed and reinvigorated Fund.

Comment

The health and wellbeing of Indigenous adolescents: a global collective for an equitable and sustainable future

Global Collective for Indigenous Adolescent Health and Evidence-Based Action

Offline: COVID-19 as culture war

Richard Horton

Viewpoint

COVID-19 vaccine strategies must focus on severe disease and global equity

Peter B McIntyre, et al.

[Excerpt]

Global COVID-19 vaccine strategies in 2022

- :: COVID-19 vaccine strategies should continue to prioritise prevention of severe disease
- :: Variants of concern such as delta and potentially omicron render strategies aimed at SARS-CoV-2 transmission unlikely to have more than a short-term effect on preventing severe COVID-19
- :: In countries with a high prevalence of previous infection and a low proportion of the population being older than 60 years prioritising delivery of the first dose will have the greatest effect on preventing severe COVID-19
- :: In countries with a low prevalence of previous infection and a high proportion of the population being older than 60 years, protection against severe disease in adults requires at least two doses
- :: In people who are severely immunocompromised or older than 60 years, evidence supports booster doses of mRNA or adenoviral vector vaccines to prevent severe disease; booster doses for all adults could compromise timely global availability of first doses

The Lancet Child & Adolescent Health

Jan 2022 Volume 6 Number 1 p1-70, e1-e4

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Jan 2022 Volume 4 Number 1 e1-e74

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Jan 2022 Volume 10 Number 1 e1-e153

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Jan 2022 Volume 22 Number 1 p1-150, e1-e40

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Jan 2022 Volume 7 Number 1 e1-e92

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Jan 2022 Volume 10 Number 1 p1-120, e1-e10

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

Maternal and Child Health Journal

Volume 25, issue 12, December 2021

<https://link.springer.com/journal/10995/volumes-and-issues/25-12>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 42 Issue 1, January 2022

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 99, Issue 4 Pages: 853-1206 December 2021

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Nature

Volume 601 Issue 7893, 20 January 2022

<https://www.nature.com/nature/volumes/601/issues/7893>

News Feature | 18 January 2022

[The pandemic's true death toll: millions more than official counts](#)

Countries have reported some five million COVID-19 deaths in two years, but global excess deaths are estimated at double or even quadruple that figure.

Nature Biotechnology

Volume 40 Issue 1, January 2022

<https://www.nature.com/nbt/volumes/40/issues/1>

World View | 07 January 2022

[Expanding global access to genetic therapies](#)

It is time to rethink intellectual property and pricing practices that prevent global access to genetic therapies.

Anne W. T. Muigai

Review Article | 20 December 2021

[Single-cell immunology of SARS-CoV-2 infection](#)

This Review provides an overview of existing studies using single-cell technologies to provide insights over the immune responses and molecular mechanisms at work in COVID-19.

Yuan Tian, Lindsay N. Carpp, Raphael Gottardo

Analysis | 06 September 2021

[Integrated analysis of plasma and single immune cells uncovers metabolic changes in individuals with COVID-19](#)

The immune cells of individuals with COVID-19 show metabolic changes.

Jihoon W. Lee, Yapeng Su, James R. Heath

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 22 Jan 2022)

[No new digest content identified]

Nature Genetics

Volume 54 Issue 1, January 2022

<https://www.nature.com/ng/volumes/54/issues/1>

[New issue: No digest content identified]

Nature Human Behaviour

Volume 5 Issue 12, December 2021

<https://www.nature.com/nathumbehav/volumes/5/issues/12>

[Reviewed earlier]

Nature Medicine

Volume 27 Issue 12, December 2021

<https://www.nature.com/nm/volumes/27/issues/12>
[Reviewed earlier]

Nature Reviews Genetics

Volume 23 Issue 1, January 2022

<https://www.nature.com/nrg/volumes/23/issues/1>
[Reviewed earlier]

Nature Reviews Immunology

Volume 22 Issue 1, January 2022

<https://www.nature.com/nri/volumes/22/issues/1>
[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 21 Issue 1, January 2022

<https://www.nature.com/nrd/volumes/21/issues/1>
[Reviewed earlier]

New England Journal of Medicine

January 20, 2022 Vol. 386 No. 3

<http://www.nejm.org/toc/nejm/medical-journal>
Perspective

[Research Participation in Marginalized Communities — Overcoming Barriers](#)

K. Armstrong and C. Ritchie

Clinical Practice

[Rapid Diagnostic Testing for SARS-CoV-2](#)

P.K. Drain

Pediatrics

Volume 149, Issue 1 January 2022

<https://pediatrics.aappublications.org/>
[Reviewed earlier]

PharmacoEconomics

Volume 40, issue 1, January 2022

<https://link.springer.com/journal/40273/volumes-and-issues/40-1>
Systematic Review

[Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review](#)

Authors (first, second and last of 4) Thomas Ward, Ruben E. Mujica-Mota, Antonieta Medina-Lara
Published: 29 October 2021

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 22 Jan 2022)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 22 Jan 2022)

[No new digest content identified]

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 22 Jan 2022)

[Reporting bias in clinical trials: Progress toward transparency and next steps](#)

Mayookha Mitra-Majumdar, Aaron S. Kesselheim

Perspective | published 19 Jan 2022 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1003894>

[Clinical impact of vivax malaria: A collection review](#)

Aung Pyae Phyo, Prabin Dahal, Mayfong Mayxay, Elizabeth A. Ashley

Collection Review | published 18 Jan 2022 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1003890>

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 22 Jan 2022)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 22 Jan 2022]

Research Article

[COVID-19 vaccine hesitancy and associated factors according to sex: A population-based survey in Salvador, Brazil](#)

Nivison Nery Jr., Juan P. Aguilar Ticona, Cristiane W. Cardoso, Ana Paula Pitanga Barbuda Prates, Helena Cristina Alves Vieira, Andrea Salvador de Almeida, Mirela Maisa da Silva Souza, Olivete Borba dos Reis, Maysa Pellizzaro, Moyra Machado Portilho, Renan Rosa da Anunciação, Renato Victoriano, Rosângela Oliveira dos Anjos, Hernán Dario Argibay, Douglas Oliveira Carmo Lima, Isadora Lima Mesquita, Wesley Mota Conceição, Perla Machado Santana, Elaine Carvalho Oliveira, Pamela Santos Nascimento Santana, Claudia Ida Brodskyn, Deborah Bittencourt Mothé Fraga, Manuela da Silva Solcà, Mitermayer Galvão Reis, Federico Costa, Guilherme S. Ribeiro

Research Article | published 21 Jan 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0262649>

[Analysis of social combinations of COVID-19 vaccination: Evidence from a conjoint analysis](#)

Hanako Ohmura

Research Article | published 21 Jan 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0261426>

[Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials](#)

Steven Kwasi Korang, Elena von Rohden, Areti Angeliki Veroniki, Giok Ong, Owen Ngalamika, Faiza Siddiqui, Sophie Juul, Emil Eik Nielsen, Joshua Buron Feinberg, Johanne Juul Petersen, Christian Legart, Afoke Kokogho, Mathias Maagaard, Sarah Klingenberg, Lehana Thabane, Ariel Bardach, Agustín Ciapponi, Allan Randrup Thomsen, Janus C. Jakobsen, Christian Gluud

Research Article | published 21 Jan 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0260733>

[The impact of free vaccination policies under the Korean Influenza National Immunization Program: Trends in influenza vaccination rates in South Korea from 2010 to 2019](#)

Jeongmin Seo, Juwon Lim

Research Article | published 20 Jan 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0262594>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 22 Jan 2022]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

December 28, 2021; vol. 118 no. 52

<https://www.pnas.org/content/118/52>

Social Sciences

Open Access

[Ethics and society review: Ethics reflection as a precondition to research funding](#)

Michael S. Bernstein, Margaret Levi, David Magnus, Betsy A. Rajala, Debra Satz, and Charla Waeiss

PNAS December 28, 2021 118 (52) e2117261118; <https://doi.org/10.1073/pnas.2117261118>

Significance

Research fields that hold transformative possibilities for improving the human condition also raise risks of negative ethical and societal outcomes. These ethical and societal risks fall outside the purview of most research reviews. We introduce an iterative review process that draws these fields into reflection and mitigation of ethical and societal risks by conditioning access to grant funding on completion of the process. A 1-y evaluation of our approach with an artificial intelligence funding program at our university suggests that this approach is well-received by researchers and positively influenced the design of their research. This process has also generated lists of common risks and mitigation strategies, to provide scaffolding for future processes.

Abstract

Researchers in areas as diverse as computer science and political science must increasingly navigate the possible risks of their research to society. However, the history of medical experiments on vulnerable individuals influenced many research ethics reviews to focus exclusively on risks to human subjects rather than risks to human society. We describe an Ethics and Society Review board (ESR), which fills this moral gap by facilitating ethical and societal reflection as a requirement to access grant funding: Researchers cannot receive grant funding from participating programs until the researchers complete the ESR process for their proposal. Researchers author an initial statement describing their proposed research's risks to society, subgroups within society, and globally and commit to mitigation strategies for these risks. An interdisciplinary faculty panel iterates with the researchers to refine these risks and mitigation strategies. We describe a mixed-method evaluation of the ESR over 1 y, in partnership with a large artificial intelligence grant program at our university. Surveys and interviews of researchers who interacted with the ESR found 100% (95% CI: 87 to 100%) were willing to continue submitting future projects to the ESR, and 58% (95% CI: 37 to 77%) felt that it had influenced the design of their research project. The ESR panel most commonly identified issues of harms to minority groups, inclusion of diverse stakeholders in the research plan, dual use, and representation in datasets. These principles, paired with possible mitigation strategies, offer scaffolding for future research designs.

Open Access

[The role of non–COVID-specific and COVID-specific factors in predicting a shift in willingness to vaccinate: A panel study](#)

Kathleen Hall Jamieson, Daniel Romer, Patrick E. Jamieson, Kenneth M. Winneg, and Josh Pasek
PNAS December 28, 2021 118 (52) e2112266118; <https://doi.org/10.1073/pnas.2112266118>

Prehospital & Disaster Medicine

Volume 36 - Issue 6 - December 2021

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 154 January 2022

<https://www.sciencedirect.com/journal/preventive-medicine/vol/154/suppl/C>

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Proceedings of the Royal Society B

26 January 2022 Volume 289 Issue 1967

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue; No digest content identified]

Public Health

Volume 202 Pages 1-138 (January 2022)

<https://www.sciencedirect.com/journal/public-health/vol/202/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 14, Issue 3, November 2021

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Reports

Volume 136 Issue 6, November/December 2021

<https://journals.sagepub.com/toc/phrg/136/6>

[Reviewed earlier]

Qualitative Health Research

Volume 32 Issue 2, January 2022

<https://journals.sagepub.com/toc/qhra/current>

[Reviewed earlier]

Research Ethics

Volume 18 Issue 1, January 2022

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 22 Jan 2022]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Selected Articles

19 Jan 2022

[Efforts towards the consolidation of public policies for the prevention of HPV-associated cancers in Puerto Rico](#)

Special report | Spanish |

19 Jan 2022

[Analysis of budgetary impact of COVID-19 vaccination in Latin America](#)

Original research | Spanish |

19 Jan 2022

[COVID-19 morbidity and mortality associated with chronic disorders, healthcare services, and inequity: evidence for a syndemic](#)

Original research | Portuguese |

Risk Analysis

Volume 41, Issue 11 Pages: 1957-2176 November 2021

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 22 Jan 2022]

[No new digest content identified]

Science

Volume 375| Issue 6578| 21 Jan 2022

<https://www.science.org/toc/science/current>

Editorial

Strengthening scientific integrity

Download PDF

BY Alondra Nelson, Jane Lubchenco

11 Jan 2022: 247-24

A robust democracy requires a common well-spring of reliable information. During his first days in office, US President Biden affirmed that evidence-based decision-making—informed by vigorous science and unimpeded by political interference—would be a pillar of his administration. He directed ambitious actions to implement that goal, including the creation of an interagency Scientific Integrity Task Force, which has just released the first-ever, comprehensive assessment of scientific integrity policy and practices in the US government.

The task force included 48 scientists, statisticians, engineers, lawyers, and policy-makers with a diversity of experiences from 29 federal agencies, and it received input from hundreds of outside experts from academia, the nonprofit sector, industry, and the public. The group found that although federal agency science is generally sound—that is, reported violations of scientific integrity policies are small in number compared to the magnitude of the federal scientific enterprise—there have been lapses that could undermine public trust in science and jeopardize federal scientists' and technologists' morale and motivation to innovate.

For example, during Hurricane Dorian's approach in 2019, then US President Trump tweeted information contradicting the official forecast of scientists at the National Oceanic and Atmospheric Administration (NOAA). Senior political leadership then directed NOAA to issue a press release supporting the president's inaccurate forecast, in effect manipulating scientific information, jeopardizing public safety, and undermining public confidence in government. In another instance, the Trump administration added a citizenship question to the 2020 census, overruling Census Bureau scientists who cited clear evidence that doing so would depress the response rate and could jeopardize census quality.

These and other violations informed the task force's recommendations, including the importance of best practices that continually reinforce a culture of integrity across the government. The report recommends the creation of a permanent interagency Scientific Integrity Council to facilitate dissemination and uptake of best practices, and communication training for scientists so that they can be more effective in explaining results to their policy superiors, to the media, and to the public. It also emphasizes the importance of meaningful and appropriate consequences for violations.

In 2009, under US President Obama, the Office of Science and Technology Policy (OSTP) identified six principles of scientific integrity: science and technology positions in the executive branch should be filled by candidates with appropriate experience; agencies should have rules to ensure the integrity of their scientific process; research that informs agency decisions should be subject to peer review; barring restrictions, scientific or technological findings that inform policy decisions should be available to the public; agencies should address instances in which the integrity of scientific and technological processes and information may be compromised; and agencies should adopt procedures that ensure the integrity of scientific and technological processes and information used to inform decision-making.

Drawing on the 2021 task force report, the OSTP now proposes five additional principles. Because science benefits from dissent within the scientific community to sharpen ideas and thinking, scientists' ability to freely voice legitimate disagreement should not be constrained. Another principle is that scientific integrity policies should apply to all federal agencies and departments engaged in the production, analysis, use, and communication of evidence, science, and technology. Moreover, these policies must apply to political appointees, career employees, and contractors. A further principle is grounded in the knowledge that science needs to be understood and actively considered during decision-making. Therefore, scientists should routinely participate actively in policy-making. Also, to promote accountability to the American public, federal scientists should be able to speak freely about their unclassified research, including to the press. And, accountability must be upheld. Violations of scientific integrity policies should be taken seriously and considered comparable to violations of government ethics rules.

In phase two, OSTP will work to implement these best practices and make the new principles operational. Every day, federal scientists and technologists help to tackle the greatest challenges that society faces. Let's make sure that this crucial work is supported and protected.

Policy Forum

[How privacy's past may shape its future](#)

BY Alessandro Acquisti, Laura Brandimarte, Jeff Hancock

20 Jan 2022: 270-272

An account of privacy's evolutionary roots may hold lessons for policies in the digital age

Abstract

Continued expansion of human activities into digital realms gives rise to concerns about digital privacy and its invasions, often expressed in terms of data rights and internet surveillance. It may thus be tempting to construe privacy as a modern phenomenon—something our ancestors lacked and technological innovation and urban growth made possible. Research from history, anthropology, and ethnography suggests otherwise. The evidence for peoples seeking to manage the boundaries of private and public spans time and space, social class, and degree of technological sophistication. Privacy—not merely hiding of data, but the selective opening and closing of the self to others—appears to be both culturally specific and culturally universal ([1](#)). But what could explain the simultaneous

universality and diversity of a human drive for privacy? An account of the evolutionary roots of privacy may offer an answer and teach us about privacy's digital future and how to manage it (2).

Reports

[SARS-CoV-2 vaccine protection and deaths among US veterans during 2021](#)

BY

Barbara A. Cohn, Piera M. Cirillo, Caitlin C. Murphy, Nickilou Y. Krigbaum, Arthur W. Wallace

04 Nov 2021: 331-336

Open Access

Vaccine protection against SARS-CoV-2 infection declined through August 2021 as the Delta variant emerged in the United States. We report severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine effectiveness against infection (VE-I) and death (VE-D) by vaccine type in 780,225 veterans in the Veterans Health Administration, covering 2.7% of the US population.

Science Translational Medicine

Volume 14| Issue 628| 19 Jan 2022

<https://www.science.org/toc/stm/current>

Research Articles

[A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus](#)

BY William A. Fischer II, et al.

19 Jan 2022

Open Access

Molnupiravir (800-mg dose) accelerated SARS-CoV-2 RNA clearance in patients with COVID-19 compared to placebo.

Social Science & Medicine

Volume 292 January 2022

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/292/suppl/C>

Research article Full text access

[What drives beliefs in COVID-19 conspiracy theories? The role of psychotic-like experiences and confinement-related factors](#)

Simão Ferreira, Carlos Campos, Beatriz Marinho, Susana Rocha, ... Nuno Barbosa Rocha

Article 114611

Research article Open access

["Please, you go first!" preferences for a COVID-19 vaccine among adults in the Netherlands](#)

Niek Mouter, Annamarie de Ruijter, G. Ardine de Wit, Mattijs S Lambooi, ... Roselinde Kessels

Article 114626

Research article Open access

[Altruism and vaccination intentions: Evidence from behavioral experiments](#)

Maria Cucciniello, Paolo Pin, Blanka Imre, Gregory A. Porumbescu, Alessia Melegaro

Article 114195

Research article Full text access

Frames that matter: Increasing the willingness to get the Covid-19 vaccines

Sean M. Diamant, Ayse Kaya, Ellen B. Magenheim

Article 114562

Research article Full text access

Pharmaceutical messianism and the COVID-19 pandemic

Gideon Lasco, Vincen Gregory Yu

Article 114567

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 22 Jan 2022]

Machine learning reduced workload for the Cochrane COVID-19 Study Register: development and evaluation of the Cochrane COVID-19 Study Classifier

This study developed, calibrated and evaluated a machine learning (ML) classifier designed to reduce study identification workload in maintaining the Cochrane COVID-19 Study Register (CCSR), a continuously upd...

Authors: Ian Shemilt, Anna Noel-Storr, James Thomas, Robin Featherstone and Chris Mavergames

Citation: Systematic Reviews 2022 11:15

Content type: Methodology

Published on: 22 January 2022

Theoretical Medicine and Bioethics

Volume 42, issue 3-4, August 2021

<https://link.springer.com/journal/11017/volumes-and-issues/42-3>

Special Issue: A plea for an experimental philosophy of medicine

Editorial Notes

A plea for an experimental philosophy of medicine

Andreas De Block & Kristien Hens

This special issue aims to explore and investigate a new subfield, namely experimental philosophy of medicine. Whereas experimental philosophy is relatively new on the philosophical block, some of its takes and findings have already shaped central debates in ethics, philosophy of action, philosophy of language, and epistemology. Interestingly, the approach of this program was for a long time almost wholly ignored within bioethics and philosophy of medicine—although this seems to have changed somewhat recently. In this introduction, we briefly sketch the program of experimental philosophy and how it can be used to shed philosophical light on issues in the philosophy of medicine.

Travel Medicine and Infectious Diseases

Volume 45 January–February 2022

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/45/suppl/C>

Research article Open access

Differentiating COVID-19 and dengue from other febrile illnesses in co-epidemics: Development and internal validation of COVIDENGUE scores

Patrick Gérardin, Olivier Maillard, Léa Bruneau, Frédéric Accot, ... Cécile Levin

Article 102232

Research article Open access

Attitudes, practices, and obstacles towards influenza vaccination for international travelers among travel health advisors in Germany: A questionnaire-based survey

Thomas Theo Brehm, Sabine Jordan, Marylyn M. Addo, Michael Ramharter, Benno Kreuels

Article 102233

Tropical Medicine & International Health

Volume 27, Issue 1 Pages: i-iv, 1-119 January 2022

<https://onlinelibrary.wiley.com/toc/13653156/current>

SERIES ON ADOLESCENT HEALTH

Free Access

Adolescent Health Series: Engagement with young people as partners in health research: Four case studies from Sub-Saharan Africa

Aoife M. Doyle, Chido Dziva Chikwari, Nomathamsanqa Majozi, Musonda Simwinga, Gracious R. Mayingire, Kelvin Simbeye, Stefanie Dringus, Sarah Bernays

Pages: 2-12

First Published: 03 December 2021

Existing health services for young people (YP)(10–24 years), which are predominantly designed for but not *with* young people, often do not meet YP's needs. The 2018 Global Consensus Statement on meaningful adolescent and youth engagement affirms that YP have a fundamental right to actively and meaningfully engage in all matters that affect their lives. We present four case studies from three countries in sub-Saharan Africa as practical examples of the engagement of young people as partners in health research. We critically reflect on best practices to inform and guide the increasing adoption of collaborative approaches.

Vaccine

Volume 40, Issue 1 Pages 1-172 (3 January 2022)

<https://www.sciencedirect.com/journal/vaccine/vol/40/issue/1>

Discussion Full text access

Inclusiveness of prisons in COVID-19 vaccination deployment: Evidence from Jordan

Saverio Bellizzi, Chinara Aidyalieva, Ala'a Al-Shaikh, Nazeema Muthu, ... Jamela Al-Raiby

Pages 1-2

Discussion Full text access

Moving the needle on racial disparity: COVID-19 vaccine trust and hesitancy

Cheryl Lin, Pikuei Tu, Thomas C. Terry

Pages 5-8

Short communication Abstract only

Improved childhood immunization coverage using the World Health Organization's Tailoring Immunization Programmes guide (TIP) in a regional centre in Australia

Susan Thomas, David Durrheim, Fakhrul Islam, Helen Higgins, Patrick Cashman

Pages 18-20

Research article Abstract only

[Validity of maternal recall for estimating childhood vaccination coverage – Evidence from Nigeria](#)

Paul Eze, Chioma Lynda Aniebo, Ujunwa Justina Agu, Sergius Alex Agu, Yubraj Acharya
Pages 28-36

Research article Full text access

[A retrospective analysis of social media posts pertaining to COVID-19 vaccination side effects](#)

Max-Philipp Lentzen, Viola Huebenthal, Rolf Kaiser, Matthias Kreppel, ... Matthias Zirk
Pages 43-51

Research article Open access

[Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial](#)

Carolina Porras, Joshua N. Sampson, Rolando Herrero, Mitchell H. Gail, ... Aimée R. Kreimer
Pages 76-88

Research article Full text access

[Perceived facilitators and barriers to intentions of receiving the COVID-19 vaccines among elderly Chinese adults](#)

Tianen Chen, Minhao Dai, Shilin Xia
Pages 100-106

Research article Open access

[Child vaccination in sub-Saharan Africa: Increasing coverage addresses inequalities](#)

Firew Tekle Bobo, Augustine Asante, Mirkuzie Woldie, Angela Dawson, Andrew Hayen
Pages 141-150

Research article Full text access

[Individual factors influencing COVID-19 vaccine acceptance in between and during pandemic waves \(July–December 2020\)](#)

Sara Valckx, Jonas Crèvecoeur, Frederik Verelst, Maren Vranckx, ... Thomas Neyens
Pages 151-161

Value in Health

January 2022 Volume 25 Issue 1 p1-160

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

.....
.....

[Pre-Print Servers](#)

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 22 Jan 2022]

[No new digest content identified]

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

medRxiv is a free online archive and distribution server for complete but [unpublished manuscripts](#) (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles... January 22, 2022 - No digest content identified

January 21, 2022

[A booster dose of mRNA-based COVID-19 vaccines fosters the development of an immune response in immunosuppressed fragile patients.](#)

Elena Azzolini, Chiara Pozzi, Luca Germagnoli, Bianca Oresta, Nicola Carriglio, Mariella Calleri, Carlo Selmi, Maria De Santis, Silvia Finazzi, Carmelo Carlo-Stella, Alexia Bertuzzi, Francesca Motta, Angela Ceribelli, Alberto Mantovani, Fabrizio Bonelli, Maria Rescigno

medRxiv 2022.01.21.22269633; doi: <https://doi.org/10.1101/2022.01.21.22269633>

[The Global case-fatality rate of COVID-19 has been declining disproportionately between top vaccinated countries and the rest of the world](#)

Najmul Haider, Mohammad Nayeem Hasan, Rumi Ahmed Khan, David McCoy, Francine Ntoumi, Osman Dar, Rashid Ansumana, Md. Jamal Uddin, Alimuddin Zumla, Richard A Kock

medRxiv 2022.01.19.22269493; doi: <https://doi.org/10.1101/2022.01.19.22269493>

[Safety Profile of Sinopharm COVID-19 Vaccine and Breakthrough Infections in Pakistan](#)

Wajiha Rizwan, Ahmad Uzair Qureshi, Muhammad Nasir Rana, Mubeen Nazar Duggal, Muhammad Sohaib, Masood Sadiq

medRxiv 2022.01.18.22268965; doi: <https://doi.org/10.1101/2022.01.18.22268965>

[mRNA-COVID19 vaccination can be considered safe and tolerable for frail patients](#)

Maria Teresa Lupo Stanghellini, Serena Di Cosimo, Massimo Costantini, Sara Monti, Renato Mantegazza, Alberto Mantovani, Carlo Salvarani, Pier Luigi Zinzani, Matilde Inglese, Fabio Ciceri, Giovanni Apolone, Gennaro Ciliberto, Fausto Baldanti, Aldo Morrone, Valentina Sinno, Franco Locatelli, Stefania Notari, Elena Turola, Diana Giannarelli, Nicola Silvestris

medRxiv 2022.01.18.22269351; doi: <https://doi.org/10.1101/2022.01.18.22269351>

[One vaccine to counter many diseases? Modelling the economics of oral polio vaccine against child mortality and COVID-19](#)

Angela Y Chang, Peter Aaby, Michael S Avidan, Christine S Benn, Stefano M Bertozzi, Lawrence Blatt, Konstantin Chumakov, Shabaana A Khader, Shyam Kottitil, Madhav Nekkar, Mihai G Netea, Annie Sparrow, Dean T Jamison

medRxiv 2022.01.19.22269560; doi: <https://doi.org/10.1101/2022.01.19.22269560>

Wellcome Open Research [to 22 Jan 2022]
<https://wellcomeopenresearch.org/browse/articles>
[Accessed 22 Jan 2022]

Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.

Research Article metrics

Revised

[An agency mapping of marginalized communities and aid providers during the COVID-19 pandemic in Malaysia](#) [version 2; peer review: 1 approved]

Melati Nungsari, Chuah Hui Yin, Nicole Fong, Veena Pillai

Peer Reviewer Zinette Bergman

Funder - World Health Organization

LATEST VERSION PUBLISHED 20 Jan 2022

* * * *

Think Tanks

Brookings [to 22 Jan 2022]
<http://www.brookings.edu/>
Accessed 22 Jan 2022
[No new digest content identified]

Chatham House [to 22 Jan 2022]
<https://www.chathamhouse.org/>
Accessed 22 Jan 2022
[No new digest content identified]

CSIS
<https://www.csis.org/>
Accessed 22 Jan 2022
Report
[Will America Squander Its New Sputnik Moment?](#)
January 19, 2022 | By [Walter G. Copan](#), [Andrei Iancu](#)

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
Accessed 22 Jan 2022
January 20, 2022 *News Release*

[How are Large Private Insurers Covering At-Home Rapid Tests?](#)

Less than a week after a new federal mandate to cover such products took effect, about half of the nation's largest private insurers allow enrollees to directly obtain rapid at-home COVID-19 tests from

specific sources without having to pay anything upfront, a new KFF analysis finds. The new coverage requirement...

January 19, 2022 *News Release*

Biden Counties Continue to Have Higher Vaccination Rates Compared to Trump Counties, As the Omicron Variant Surges Across the U.S.

An updated KFF analysis finds that counties that voted for Biden continue to have higher COVID-19 vaccination rates compared to counties that voted for Trump. As of January 11, 65% of those in Biden counties were fully vaccinated versus 52% of those in Trump counties. Even with the Omicron variant...

Rand [to 22 Jan 2022]

<https://www.rand.org/pubs.html>

Reports, Selected Journal Articles

Report

Changes in School Composition During the COVID-19 Pandemic: Implications for School-Average Interim Test Score Use

The coronavirus disease 2019 pandemic has exacerbated concerns about using school-aggregate test scores to monitor school performance. In this report, researchers investigate how changes to school composition may contaminate aggregate scores.

Jan 19, 2022

Jonathan Schweig, Megan Kuhfeld, Melissa Kay Diliberti, Andrew McEachin, Louis T. Mariano

Urban Institute [to 22 Jan 2022]

<https://www.urban.org/publications>

Publications

Support for Mask and Vaccine Policies in Schools Falls along Racial and Political Lines

As COVID-19 rates rise again with the emergence of the omicron variant and roll school reopening plans, local educational leaders are faced with tough decisions about school policies. Though arguably these decisions should be informed by science, administrators must also consider how parents will respond. As the pandemic persists and new variants emerge, the partisan divide over COVID-19 mitigation strategies

Dan Silver, Michael Fienberg, Morgan Polikoff

January 13, 2022

Brief

*

*

*

*

Contents [click to move among sections]

::

Milestones - Perspectives

:: *Coronavirus [COVID-19] - WHO*

:: *Emergencies*

:: *Organization Announcements*

:: *Journal Watch*

* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2021. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute , PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *